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THE ROLE OF BCL-2 FAMILY IN CLINICAL RESPONSE OF 
CHRONIC LYMPHOCYTIC LEUKEMIA 
 
SAYER ALHARBI 
 
ABSTRACT 
     The anti-apoptotic Bcl-2 proteins regulate lymphocyte survival and are over-
expressed in lymphoid malignancies, including chronic lymphocytic leukemia 
(CLL). The small molecule inhibitor ABT-737 binds with high affinity to Bcl-2, 
Bcl-xl, and Bcl-w but with low affinity to Mcl-1, Bfl-1, and Bcl-b. The active 
analog of ABT-737, navitoclax, has shown a high therapeutic index in lymphoid 
malignancies; developing a predictive marker for it would be clinically valuable 
for patient selection or choice of drug combinations. We compared expression of 
anti-apoptotic Bcl-2 genes that are known to be targeted by ABT-737. Our 
findings reveal that the relative ratio of Mcl-1 and Bfl-1 to Bcl-2 expression 
provides a highly significant linear correlation with ABT-737 sensitivity (r = 0.6, 
P < .001). The (Mcl-1 + Bfl-1)/Bcl-2 ratio was validated in a panel of leukemic 
cell lines subjected to genetic and pharmacologic manipulations. We also tested 
whether anti-apoptotic Bcl-2 proteins can be used as prognostic marker in CLL, 
since the current prognostic markers, such as CD38 and ZAP70 fail to predict the 
clinical outcome in a substantial number of CLL patients. Our findings indicate 
that only high Bcl-xl expression is strongly correlated (P=0.002) with short 
 V 
treatment-free survival. Strikingly, Bcl-xl was able to identify patients with high 
risk in the ZAP70 negative and CD38 negative groups as well as in patients with 
normal/unknown p53 deletion, thus providing a very powerful prognostic value 
for CLL.  Finally, we investigated the potential mechanism responsible for ABT-
737 resistance in leukemic cell lines. Compared with parental cells, cells that have 
developed acquired resistance to ABT-737 showed increased expression of Mcl-1 
due to increased protein stability. Interestingly, increased Mcl-1 levels sequester 
the BH3-only protein Bim which mediates resistance to ABT-737. These data 
therefore reveal novel insights into the role of anti-apoptotic Bcl-2 proteins in 
clinical response, acquired resistance, and tumor progression in CLL patients. 
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CHAPTER I 
INTRODUCTION 
 
1.1 Apoptosis 
     Apoptosis, or programmed cell death, is a cellular mechanism used to eliminate 
cells that are injured, infected, or have reached the end of their life span (Kerr, 
Wyllie et al. 1972). This process is tightly regulated by a family of proteases called  
caspases, which are normally found in healthy cells as inactive precursors, but which 
become activated during apoptosis (Autret and Martin 2009). Apoptosis ensures 
removal of cellular bodies before these cells can rupture and release their contents. 
This process is critical, as cell rupture caused by necrosis can provoke inflammatory 
immune reactions that can augment promote damage and lead to further cell death 
(Chen, Kono et al. 2007). Disturbed regulation of apoptosis can lead to many 
diseases, including cancer, autoimmunity, and degenerative disorders (Cory and 
Adams 2002). Apoptotic cell death is characterized by a series of morphological and 
biochemical features, such as plasma membrane blebbing, chromatin condensation, 
DNA cleavage, and exposure of phosphatidylserine on the extracellular side of the 
plasma membrane (Bouillet and Strasser 2002).  
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1.2 Apoptosis pathways 
     There are two predominant pathways that cells utilize to trigger apoptosis. The 
two pathways of apoptosis can be distinguished by whether the Bcl-2 family 
proteins are involved and which caspases are critical for mediating the cell death 
(Youle and Strasser 2008). The intrinsic pathway or mitochondrial pathway is 
mediated by the Bcl-2 family and primarily leads to the activation of caspase-9 
(Hakem, Hakem et al. 1998). The Bcl-2 family consists of anti and pro-apoptotic 
members that mediate opposing functions to control life or cell death in the 
intrinsic pathway by controlling the integrity of the outer mitochondrial 
membrane (OMM).  
     Bcl-2 family members are classified into anti-apoptotic and pro-apoptotic 
(Chipuk, Moldoveanu et al. 2010). Anti-apoptotic members include Bcl-2-related 
gene (Bcl-2), Bcl-2-related gene A1 (A1), long isoform (Bcl-xl), Bcl-2-like 2 
(Bcl-w), Bcl-b and myeloid cell leukemia 1 (Mcl-1). The anti-apoptotic members 
work predominantly to inhibit apoptosis by sequestering pro-apoptotic proteins 
and blocking their ability to oligomerize and advance the outer mitochondrial 
membrane permeabilization (OMMP).  The pro-apoptotic Bcl-2 members are 
divided into the effector proteins and the BH3-only proteins. The effector proteins 
Bcl-2 antagonist killer 1 (Bak) and Bcl-2-associated x protein (Bax) can initiate 
apoptosis by causing pores within the OMM to promote MOMP. The BH3-only 
proteins Bad, Bid, Bim, Noxa, and Puma have a conserved BH3 domain that can 
bind to the anti-apoptotic Bcl-2 proteins and thus allow the effector proteins to be 
released and then promote apoptosis. 
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     The intrinsic pathway can be triggered by various intracellular stresses, 
including cytokine deprivation and genotoxic damage (Zha, Harada et al. 1996; 
Oda, Ohki et al. 2000) (Figure 1.1). Once the intrinsic pathway is triggered, this 
promotes MOMP, which allows cytochrome c, located in the mitochondrial 
intermembrane space (IMS), to be released into the cytosol. Cytochrome c 
engages apoptotic protease activating factor-1 (APAF-1) to oligomerize into a 
caspase activation complex called the apoptosome. This binds and promotes the 
activation of initiator caspase-9, which then activates executioner caspases-3 and -
7 (Li, Nijhawan et al. 1997). 
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Figure 1.1: Scheme showing intrinsic and extrinsic pathways of apoptosis. 
Apoptosis can be induced by intrinsic or extrinsic pathways. The intrinsic 
pathway is activated either by BH3-only protein induction or by post-translational 
modification which resulted in inhibition of the anti-apoptotic Bcl-2 proteins. This 
releases BAK or BAX, which in turn release cytochrome c and promote apoptosis 
by activating APAF1 and caspases. The extrinsic pathway can be activated 
directly by caspase-8, which leads to caspase-3 activation and cell death.  The 
intrinsic pathway can be linked to the extrinsic pathway through cleaved BID. 
Modified from (Youle and Strasser 2008). 
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     The extrinsic pathway is activated by ligation of death receptors at the cell 
surface independently of the Bcl-2 family. The tumor necrosis factor (TNF) 
receptor family members, such as Fas or TNF receptor-1 (TNFR1), contain an 
intracellular death domain that can recruit and activate caspase-8 through the 
adaptor protein Fas-associated death domain (FADD). This recruitment leads to 
activation of downstream caspases, such as caspase-3, -6, or -7 (Ashkenazi 2002; 
Almasan and Ashkenazi 2003). Interestingly, the extrinsic pathway can be linked 
with the intrinsic pathway through caspase-8 cleavage-mediated activation of the 
pro-apoptotic BH3-only protein Bid (Li, Zhu et al. 1998; Luo, Budihardjo et al. 
1998). The cleaved Bid (tBid) can translocate to the mitochondria and further 
activate caspase through the intrinsic pathway (Figure 1.1). 
 
1.3 Bcl-2 family structure 
     The Bcl-2 family shares at least one conserved homology domain, called the 
Bcl-2 homology (BH) domain (Youle and Strasser 2008) (Figure 1.2). Anti-
apoptotic Bcl-2 proteins contain four Bcl-2 homology domains (BH1–4) and are 
mostly localized within the OMM. The carboxy terminal hydrophobic 
transmembrane domain (TM) of the anti-apoptotic Bcl-2 proteins mediates its 
targeting to the outer mitochondrial membrane, where the BH1-BH3 domains and 
the N-terminal BH4 domain stabilizes the structure (Tzifi, Economopoulou et al. 
2012). BH1-BH3 domains also form a hydrophobic groove on the surface of anti-
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apoptotic proteins that can be targeted by the BH3 domain of their pro-apoptotic 
ligands (Sattler, Liang et al. 1997).  
     The three-dimensional structure is conserved between Bcl-xl and Bcl-2 
(Petros, Medek et al. 2001). However, there are similarities and differences 
between the Bcl-2 cores of anti-apoptotic proteins and the BH3 peptide binding 
(Chipuk, Moldoveanu et al. 2010), thus creating a preferential binding between 
anti-apoptotic and BH3-only Bcl-2 family proteins. For example, Bim and Puma 
can bind to all anti-apoptotic proteins, where Noxa binds only to Mcl-1 and Bfl-1 
(Figure 1.3). These variations in the Bcl-2 cores are critical to cancer drug 
discovery, as Mcl-1 and Bfl-1 are not targeted by the most promising BH3 
mimetic, ABT-737, which only inhibits Bcl-2, Bcl-w, and Bcl-xl (Oltersdorf, 
Elmore et al. 2005). 
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Figure 1.2: The Bcl-2 family related proteins. This family comprises anti-
apoptotic (highlighted in green boxes), pro-apoptotic (highlighted in blue) and 
BH3-only proteins (highlighted in orange). The anti-apoptotic and pro-apoptotic 
proteins share four Bcl-2 homology domains BH1-4, where BH3-only proteins 
display only one BH3 domain. Modified from (Lessene, Czabotar et al. 2008). 
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     . 
 
 
 
Figure 1.3. The binding specificity of BH3-only proteins for anti-apoptotic 
Bcl-2 family proteins.  Bim, Bid and Puma can bind to all anti-apoptotic Bcl-2 
family proteins. Noxa binds only to Mcl-1 and Bfl-1 (A1), where as Bad binds to 
Bcl-1, Bcl-xl, and Bcl-w. Modified from (Youle and Strasser 2008). 
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     The effector proteins Bax and Bak were first described as containing only 
BH1-3 domains, however it was later discovered that they also contain a BH4 
domain (Kvansakul, Yang et al. 2008). The BH3-only proteins contain a BH3 
domain that is essential for binding  to the anti-apoptotic members and mediating 
apoptosis (Huang and Strasser 2000). The BH3 peptide is an amphipathic α-helix 
of around 15 amino acids long that binds to the hydrophobic groove of the anti-
apoptotic Bcl-2-family proteins (Zha, Aime-Sempe et al. 1996). The BH3-only 
proteins are divided into direct activator (Bim and Bid) and sensitizers/de-
repressor (Bad, Noxa, and Puma) proteins. 
 
1.4 Bax and Bak activation models 
Initiation of apoptosis requires not only pro-apoptotic family members, such as 
Bax and Bak, but also the BH3-only proteins. However, the BH3-only proteins 
alone fail to induce apoptosis in the absence of Bax and Bak (Zong, Lindsten et 
al. 2001). During apoptosis, Bax and Bak oligomerize into the mitochondrial 
outer membrane, disrupt its integrity and release cytochrome c, which allows 
activation of caspases (Wei, Zong et al. 2001). The BH3-only proteins Bid and 
Bim can directly trigger Bax and Bak activation whereas the other members were 
suggested to activate Bax and Bak indirectly (Wei, Lindsten et al. 2000; Letai, 
Bassik et al. 2002). In fact, there are three models for activating Bax and Bak: 
sensitizer, de-repressor, and neutralization models (Chipuk, Moldoveanu et al. 
2010) (Figure 1.4).  According to  the sensitizer model, an anti-apoptotic protein 
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is sequestered with a BH3-only protein and this interaction blocks the inhibition 
of direct activators (Letai, Bassik et al. 2002). For example, if Bcl-2 is in complex 
with Puma, any further induction of Bim will not be inhibited, since Bcl-2 is 
already sequestered by Puma and in this case MOMP will proceed (Figure 1.4A). 
According to the derepression model, a direct activator is inhibited by an anti-
apoptotic Bcl-2 protein, and any cellular stress  induces a BH3-only protein, 
which then releases the direct activator from Bcl-2 and  promotes MOMP (Certo, 
Del Gaizo Moore et al. 2006; Del Gaizo Moore, Brown et al. 2007) (Figure 1.4B). 
In the neutralization model, the effecter protein Bax or Bak is inhibited (Uren, 
Dewson et al. 2007).  For example, activated Bak is sequestered by the anti-
apoptotic Bcl-2, and following any cellular stress, a BH3-only protein will be 
induced to neutralize the anti-apoptotic protein, which frees Bak, and then 
promotes apoptosis (Figure 1.4C). 
 
     Activation of Bax appears to involve sub-cellular translocation and 
oligomerization.   In healthy cells, Bax is localized as an inactive form in the 
cytosol where an α9 helix in the C-terminal occupies its BH3 binding 
hydrophobic groove, which inhibits both its mitochondrial localization and pro-
apoptotic activity (Suzuki, Youle et al. 2000).  During apoptosis, Bax undergoes 
conformational change, which allows to translocate to the mitochondria by 
inserting its C-terminal into the OMM and thus, allowing its BH3 domain 
exposure, which mediates Bax oligomerization. Unlike Bax,  Bak is localized on 
the mitochondria, where it is sequestered by anti-apoptotic Mcl-1 and Bcl-xl to 
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prevent its oligomerization (Willis, Chen et al. 2005). Following cytotoxic signals 
that activate BH3-only proteins, the interaction can be disrupted by the BH3-only 
proteins where Bak can be released from the anti-apoptotic proteins and promote 
apoptosis.   
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Figure 1.4: Three models for activating Bax and Bak by BH3-only proteins. 
(A) Sensitizer model: BH3-only protein inhibits the anti-apoptotic Bcl-2 protein. 
Upon activation following a cellular stress, a direct activator can not be inhibited 
and will go directly to promote MOMP. (B) De-repressor model. A direct 
activator (BIM) is sequestered by an anti-apoptotic Bcl-2 protein. Following 
cellular stress, a de-repressor BH3-only protein is induced and releases the direct 
activator from the anti-apoptotic protein and then MOMP proceeds. (C) The 
neutralization model: The effector BAK is inhibited by the anti-apoptotic protein. 
Following cellular stress, BH3-only protein is induced and then binds to the anti-
apoptotic protein which displaces the effector and then promotes MOMP. 
Modified from (Chipuk, Moldoveanu et al. 2010). 
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1.5 Bcl-2 family regulation 
     BH3-only proteins are the major sensors for any cellular stress. BH3-only 
proteins can be activated in a variety of ways, such as transcriptional 
upregulation, proteolysis, or post-translational modifications (Figure 1.5). Noxa 
and Puma can be induced transcriptionally by the tumor suppressor p53 in 
response to DNA damage (Oda, Ohki et al. 2000; Nakano and Vousden 2001).  
     Bim is regulated transcriptionally by the class O forkhead box transcription 
factor-3A (FOXO3A) in response to growth factor deprivation (Dijkers, Medema 
et al. 2000). Bim can be also regulated at transcriptional level, where bim mRNA 
is negatively regulated by the miRNA cluster miRNA-17-92 (Xiao, Srinivasan et 
al. 2008). In healthy cells, Bim is sequestered away from the anti-apoptotic 
proteins by binding to LC8 dynein light chain in the microtubule-associated 
dynein motor complex (Puthalakath, Huang et al. 1999). Following a death signal, 
Bim dissociates from the motor complex and translocates to neutralize Bcl-2 anti-
apoptotic activity. Moreover, phosphorylation of pro-apoptotic Bim by ERK1/2 
on serine 69 promotes its degradation by the ubiquitin-proteasome pathway 
(Luciano, Jacquel et al. 2003). 
     The BH3-only protein Bad is regulated by post-translational modification on 
two phosphorylation sites, ser-112 and ser-136. The phosphorylated Bad is 
sequestered in the cytosol by a 14-3-3 molecule that prevents interaction with 
anti-apoptotic Bcl-xl (Zha, Harada et al. 1996). The survival signaling molecule 
Akt has been shown to lead to phosphorylated Bad at ser-136 and inactivate its 
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function, however, dephosphorylated Bad can neutralize Bcl-xl to promote 
apoptosis following IL-3 deprivation (Datta, Dudek et al. 1997).    
     Interestingly, unlike other pro-apoptotic members, Bid undergoes a cleavage 
mediated by caspase-8 (Li, Zhu et al. 1998) and this cleavage allows the buried 
BH3 domain to be exposed. The cleaved Bid (tBid) can then translocate to the 
mitochondria to promote apoptosis (Figure 1.5). 
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Figure 1.5: Activation of BH3-only proteins. BH3-only proteins are activated in 
a variety of ways, including proteolysis, post-translational modifications, or 
transcriptional up regulation.  Bid is activated by cleavage, whereas Bad is kept in 
an inactive phosphorylated form bound to 14-3-3 in the cytoplasm. Following 
growth factor/cytokine deprivation, Bad is activated by de-phosphorylation. Bim 
is bound to the microtubules and released after cytokine deprivation.  Puma and 
Noxa are transcriptionally up regulated by p53 following DNA damage. The 
activated BH3-only proteins can then translocate to the mitochondria where they 
promote apoptosis by activating the effector proteins or by neutralizing the anti-
apoptotic proteins. Modified from (Gardner 2004). 
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     The anti-apoptotic protein Mcl-1 also undergoes several post-translational 
modifications since it has a large N terminal that contains two sequences rich in 
proline (P), glutamic  acid (E), serine (S), and threonine (T), which mediate rapid 
degradation or promote stability of the proteins (Gores and Kaufmann 2012). 
These modifications are critical for determining whether Mcl-1 promotes or 
prevents apoptosis. Mcl-1 protein has a unique feature that differentiates it from 
other anti-apoptotic Bcl-2 family members: it has a short half-life estimated at less 
than 1 hour (Stewart, Koss et al. 2010). The short half-life of Mcl-1 is due to 
constitutive polyubiquitination and degradation by the proteasome. It has been 
shown that following IL-3 withdrawal, Mcl-1 is phosphorylated on serine159 by 
glycogen synthase kinase-3 (GSK-3) and thus accelerating ubiquitinylation and 
degradation of Mcl-1 (Maurer, Charvet et al. 2006). Mcl-1 is ubiquitinylated by 
MULE (Mcl-1 Ubiquitin Ligase E3) at  five lysines of its N terminus (Zhong, Gao 
et al. 2005). MULE contains a BH3 domain that binds to Mcl-1 and promotes its 
degradation. FBW7 is another E3 ubiquitin ligase that has been recently identified 
to promote Mcl-1 degradation (Inuzuka, Shaik et al. 2011). It has been reported 
that removing ubiquitin groups conjugated to Mcl-1 by the deubiquitinase USP9X 
was found to increase Mcl-1 stability and thus, promote cell survival (Schwickart, 
Huang et al. 2010). USP9X binds Mcl-1 and removes the polyubiquitin chains 
that flags Mcl-1 for proteasomal degradation, which results in high Mcl-1 levels. 
Interestingly, Mcl-1 activity can be changed from anti-apoptotic to pro-apoptotic 
activity during apoptosis following cleavage by caspase-3 at Asp127 and/or 
Asp157 (Michels, O'Neill et al. 2004). 
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     Ubiquilin-1 (Ubqln1) has been identified to interact specifically with Bcl-b and 
not with other anti-apoptotic proteins. Ubqln1 promotes Bcl-b protein 
stabilization and re-localization from the mitochondria to the cytosol which leads 
to more potent anti-apoptotic activity (Beverly, Lockwood et al. 2012). 
     The anti-apoptotic protein Bcl-2 can also be regulated by post-translational 
modification; caspase-3 cleaves the carboxyl terminal at Asp34, which converts 
the Bcl-2 phenotype from anti-apoptotic to pro-apoptotic (Cheng, Kirsch et al. 
1997; Chen, Gong et al. 2000). This conformational change reveals the pro-
apoptotic activity of Bcl-2. Moreover, binding the orphan nuclear receptor Nur77 
to Bcl-2 causes a conformational change that leads to expose the buried BH3 
domain of Bcl-2 (Lin, Kolluri et al. 2004).  On the other hand, anti-apoptotic Bcl-
xl and Bfl-1 genes are directly regulated by the transcription factors signal 
transducer and activator of transcription (STAT3) and NF-kB (Grumont, Rourke 
et al. 1999; Zong, Edelstein et al. 1999; Grad, Zeng et al. 2000).  
  
1.6 Bcl-2 family and its physiological roles 
     Knockout mice studies have revealed the essential role of the Bcl-2 family in 
embryogenesis and tissue homeostasis. Bcl-xl was found to be essential for 
embryogenesis, neuronal cells, and hematopoietic cell survival (Motoyama, Wang 
et al. 1995). It has been recently shown that Bcl-xl is also critical for lymphoma 
development (Kelly, Grabow et al. 2011). Bcl-2-deficient mice show complete 
embryonic development, however, they have defects in lymphocyte 
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differentiation and severe polycystic kidney disease (Veis, Sorenson et al. 1993). 
Mcl-1 deletion was reported to be lethal due to the failure of embryonic  
implantation (Rinkenberger, Horning et al. 2000), Mcl-1 was also found to be 
critical for  the development and survival of acute myeloid leukemia (AML) cells 
(Glaser, Lee et al. 2012).  
     Bax knockout mice exhibit B-cells hyperplasia (Knudson, Tung et al. 1995), 
whereas Bak-deficient mice have been reported to be developmentally normal. 
Interestingly, Bak and Bax double knockout mice showed a huge accumulation of 
hematopoietic cells due to lack of apoptosis (Lindsten, Ross et al. 2000).  
     Gene targeting studies have defined the essential functions of different BH3-
only members in mediating apoptosis. Bid has been reported to be a critical factor 
for cell death initiated by death receptor Fas, as Bid-deficient mice were highly 
resistant to Fas-induced apoptosis (Yin, Wang et al. 1999). In addition, deleted 
Bim causes resistance to apoptosis induced by growth factor deprivation in a 
broad range of cell types (Bouillet, Metcalf et al. 1999), whereas loss of Puma and 
Noxa mediate resistance to DNA damage agents (Villunger, Michalak et al. 
2003). 
 
1.7 Bcl-2 family regulation in cancer 
     Blocking apoptosis is considered one of the hallmarks of cancer as impaired 
apoptosis maintains cancer survival and progression (Hanahan and Weinberg 
2011). Cancer cells block apoptosis either by promoting overexpression of the 
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anti-apoptotic proteins or by downregulating the pro-apoptotic proteins.  Both 
increased levels of anti-apoptotic proteins or the loss of pro-apoptotic proteins are 
associated with genetic alterations in many tumor malignancies. Chromosomal 
translocations, deletion, additional copy numbers, post-translational 
modifications, or epigenetic alterations have been reported to modulate Bcl-2 
family expression that can promote survival of cancer cells.  
     In follicular B-cell lymphoma, a high Bcl-2 expression level is associated with 
(14;18) chromosomal translocations, which place the Bcl-2 gene on chromosome 
18 under the control of an immunoglobulin heavy chain enhancer on chromosome 
14, resulting in excessive Bcl-2 production though transcriptional regulation 
(Tsujimoto, Cossman et al. 1985).  High Bcl-2 levels have also been reported in 
diffuse large B-cell lymphoma and chronic lymphocytic leukemia due to Bcl-2 
gene amplification or hypomethylation of the Bcl-2 promoter (Hanada, Delia et 
al. 1993; Monni, Joensuu et al. 1997). In addition, the single nucleotide 
polymorphisms 938 C >A in the Bcl-2 promoter enhanced its binding activity and 
resulted in high Bcl-2 levels in chronic lymphocytic leukemia cells (Nuckel, Frey 
et al. 2007).  
     Preventing Bcl-2 pro-apoptotic activity of anti-apoptotic proteins can be a 
strategy for blocking apoptosis in cancer cells. Mutation of the aspartic acid 
residue required for caspase cleavage that changes Bcl-2 function from anti-
apoptotic to pro-apoptotic has been identified in human lymphoma (Cory, Huang 
et al. 2003).  
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     Interestingly, the loss of endogenous microRNAs that normally repress anti-
apoptotic Bcl-2 protein expression can be a mechanism for elevated levels of 
these anti-apoptotic proteins. MicroRNAs are short, noncoding RNAs of about 
19–24 nt that bind to 3′ UTRs of target mRNAs and promote their degradation.  
MiR-15a and miR-16-1 are located in a cluster at 13q14.3, which are frequently 
deleted in CLL (Calin, Ferracin et al. 2005). Deletions of miR-15a and miR-16-1 
result in high Bcl-2 expression.  
     In cancer cells, Mcl-1 undergoes post-translational modification to enhance 
cell survival by increasing the rate of protein stability. Extracellular signal-
regulated kinases (ERK) activation promotes Mcl-1 phosphorylation at Thr163 
and stabilization of the Mcl-1 protein (Domina, Vrana et al. 2004).  The E3 
ubiquitin ligase that targets phosphorylated Mcl-1 for degradation has been 
recently identified as FBW7 (Inuzuka, Shaik et al. 2011).  FBW7 is a E3 ubiquitin 
ligase which controls Mcl-1 stability. FBW7 has tumor-suppressor activity, as 
mutation or deletion of this gene resulted in a significant increase in Mcl-1 levels 
in human ALL cell lines.  
     In a large study to analyze gene copy number in many cancer specimens, the 
Mcl-1 genomic region has been found to be amplified in lung and breast cancers 
(Beroukhim, Mermel et al. 2010).  MiR-29 was found to negatively regulate Mcl-
1 expression and miR-29 loss is consequently associated with high Mcl-1 levels 
(Mott, Kobayashi et al. 2007). Like Mcl-1, Bfl-1 protein has a short half-life, 
which can be markedly increased by the mutation of C-terminal lysines 151,163, 
and 172 to arginines (Fan, Simmons et al. 2010). These ubiquitination-resistant 
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mutants show that Bfl-1 deubiquitination is critical for its tumor promotion 
mechanism.   
     It has recently been reported that chromosomal translocation of the 
transcription factor BACH2 gene on 6q15 to the second exon of Bcl-xl on 20q11 
resulted in strong expression of Bcl-xl in the Burkitt lymphoma cell line BLUE-1 
(Turkmen, Riehn et al. 2011).      
     Genetic alterations in pro-apoptotic genes have also been reported in many 
cancers. These alterations can result in loss of the tumor suppressor function of 
pro-apoptotic genes. Interestingly, p53 is the transcription factor for Bax, Bid, 
Puma and Noxa; therefore, any deletion or mutation in the p53 gene will directly 
affect the transcriptional levels of these genes (Miyashita and Reed 1995; Oda, 
Ohki et al. 2000; Nakano and Vousden 2001).  Bim function is reported to be lost 
in hematological malignancies; for example, the 2q13 locus where the BIM gene 
is located has been reported to be deleted in mantle cell lymphoma (Tagawa, 
Karnan et al. 2005).  Bim expression can also be regulated transcriptionally by 
microRNA as gene amplification of miR-17 that negatively regulates Bim level is 
observed in several human cancers (Ventura, Young et al. 2008).  Mutations that 
cause inactive Bax have been reported in colon cancer (Rampino, Yamamoto et 
al. 1997).  AKT pathway is known to be highly activated in many cancers. Upon 
activation, AKT phosphorylates the pro-apoptotic protein Bad, which results in its 
sequestration by 14-3-3 (Zha, Harada et al. 1996). 
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1.8 Bcl-2 family and clinical response in cancer 
     Apoptosis is often impaired in cancer and can significantly limit the response 
to conventional therapy. Resistance of tumor cells to radiation or chemotherapy 
can be due to a defect in the apoptosis machinery. Increased anti-apoptotic protein 
levels have been reported in many human malignancies and generally correlate  
with aggressive tumors and chemotherapeutic resistance (Letai 2008). A high 
Mcl-1 level has been correlated with chemoresistance  in various haematopoietic 
and lymphoid cancers, CLL (Kitada, Andersen et al. 1998) and multiple myeloma 
(Derenne, Monia et al. 2002). Interestingly, resistance to 122 standard 
chemotherapy agents was correlated with high Bcl-xl levels in 60 NCI cell lines 
(Amundson, Myers et al. 2000). The resistance to a group of compounds that 
repress Mcl-1 expression was correlated with high mRNA expression of Bcl-xl, 
indicating that the patients-selection strategy for development of any Mcl-1 
inhibitor in breast and non-small cells lung carcinoma (NSCLC) tumors should be 
based on patients with low Bcl-xl expression (Wei, Margolin et al. 2012). High 
Bfl-1 levels were also found to contribute to fludarabine resistance in CLL cells 
(Olsson, Norberg et al. 2007).  
     Several studies have attempted to correlate Bcl-2 family expression and 
response to treatments, which highlight the potential application of the Bcl-2 
family as a marker for predicting clinical outcome. We have shown that the 
relative expression of Mcl-1 and Bfl-1 to Bcl-2 predicts ABT-737 response in 
hematological and solid malignancies (Al-Harbi, Hill et al. 2011). High levels of 
Bcl-2 and low levels of Bax were associated with resistance to chlorambucil in 
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CLL (Thomas, Pepper et al. 2000). Interestingly,  It was found that patients with 
highly primed cancer cells or a high apoptotic threshold exhibited superior 
clinical response to chemotherapy (Ni Chonghaile, Sarosiek et al. 2011).  
 
1.9 Targeting anti-apoptotic proteins by small molecule inhibitors  
     Most conventional cytotoxic therapies act primarily through p53 activation to 
induce apoptosis, and this indirect effect may explain the poor response in 
patients with p53 deletion. Thus, it can be concluded that there is a need to 
develop a new generation of targeted therapies that mediate response through 
direct activation of the apoptotic machinery. This could be a very promising 
approach since most cancer cells are addicted to high expression of anti-apoptotic 
proteins in order to maintain their survival and progression. 
Obatoclax: A screen of a natural products library for Bcl-2 inhibitors identified 
obatoclax as a molecular antagonist that binds to Bcl-2, Bcl-xl, Bcl-w, and Mcl-1 
with low micromolar affinity (Perez-Galan, Roue et al. 2007). Obatoclax has 
shown high anti-tumor activity through disruption of the Mcl-1:Bak interactions 
(Li, Viallet et al. 2008). In contrast,  another report showed that obatoclax has the 
same anti-tumor activity in Bak/Bax double knockout mice as wild type cells, and 
the anti tumor activity was similar in cells with both high and low anti-apoptotic 
proteins levels (Lessene, Czabotar et al. 2008). This leads to the conclusion that 
the cell death induced by the drug is not mediated by apoptosis and sensitivity to 
the drug was not correlated to expression levels of anti-apoptotic Bcl-2 proteins.  
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Gossypol: Another small molecule antagonist that targets anti-apoptotic proteins 
is gossypol. It is a drug derived from the cotton plant and has shown high anti-
tumor activity in several hematological malignancies, including lymphoma and 
multiple myeloma cell lines, as well as in vivo models (Paoluzzi, Gonen et al. 
2008); however, one major drawback of the drug is that its anti tumor activity 
requires a high concentration (≈20µM), which it is difficult to achieve clinically. 
ABT-737: Crystal structural studies have shown that the BH3 peptide is 16 to 20 
amino acids in length and binds a hydrophobic pocket formed by the BH1, BH2 
and BH3 domains on the surface of anti-apoptotic proteins (Muchmore, Sattler et 
al. 1996; Sattler, Liang et al. 1997).  This provides the platform for a new drug 
discovery based on mimicking BH3 peptides that can be  rational antagonists of 
the anti-apoptotic proteins.  Nuclear magnetic resonance (NMR)-based screening 
and structure-based design structure methods were applied rationally to develop a 
small molecule inhibitor that binds with high affinity to Bcl-2, Bcl-xl, and Bcl-w, 
and with low affinity to Mcl-1 and Bfl-1 (Oltersdorf, Elmore et al. 2005) (Figure 
1.6). ABT-737 has maintained its high activity even in the presence of 10% 
human serum with a minimum effect on normal primary cells derived from 
healthy donors. As compared to seven anti-apoptotic protein inhibitors, ABT-737 
was the only one to mediate cell death in a Bak/Bax-dependent manner (van 
Delft, Wei et al. 2006).  
     We have recently shown that ABT-737 activity is based on relative expression 
of Mcl-1 and Bfl-1 to Bcl-2 in hematological malignancies and small cell lung 
carcinoma (Al-Harbi, Hill et al. 2011). This indicates that ABT-737 is a highly 
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selective target. ABT-737 and its oral derivative compound navitoclax had a 
marked cytotoxic effect as a single agent in a variety of tumor types, including 
lymphoma and lung cancer when used within nanomolar range (Tse, Shoemaker 
et al. 2008). Tumor volume was significantly reduced in small cell lung cancer 
xenografts and haematological xenografts when treated with navitoclax (Tse, 
Shoemaker et al. 2008). Recent clinical trials show that the drug is highly 
effective with minimum off target-effects (Wilson, O'Connor et al. 2010; Gandhi, 
Camidge et al. 2011; Roberts, Seymour et al. 2012). 
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Figure 1.6: Interaction between anti-apoptotic protein Bcl-xl and ABT-737. 
(A)  Structure of ABT-737 binding to the hydrophobic pocket on the surface of 
anti-apoptotic Bcl-xl protein.  (B) ABT-737 chemical structure. Modified from 
(Lessene, Czabotar et al. 2008).  
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1.10 Bcl-2 family and Chronic Lymphocytic Leukemia (CLL) 
     Chronic lymphocytic leukemia (CLL) is the most common leukemia in the 
Western world, and accounts for approximately 30% of leukemia cases in the 
United States (Lee, Dixon et al. 1987). CLL is characterized by an excessive 
accumulation of morphologically mature B lymphocytes in the blood, marrow, 
and lymphatic tissues. Blocking apoptosis by high levels of anti-apoptotic 
proteins is considered the hallmark of CLL. Interestingly, it has been reported that 
high levels of Bcl-2 correlate with high white blood cell (WBC) counts in CLL 
patients (Del Gaizo Moore, Brown et al. 2007).  This leads to the conclusion that 
high B-cell counts are more likely to be a result of decreased apoptosis rather than 
of an increased in proliferation rate.  
     Clinical staging (Rai/Binet) in CLL is based on classification into three stages 
(Bazargan, Tam et al. 2012): low stage (0) is characterized by lymphocytosis 
located in the blood or bone marrow, intermediate stage (I, II) is a patient with 
lymphocytosis and enlarged lymph nodes, liver, or spleen. High stage (III, IV): is 
characterized by lymphocytosis and anemia (Hgb <11 g/dl), or lymphocytosis and 
thrombocytopenia (platelet count <100,000/μl). This clinical staging system is 
essential to estimate the tumor burden, however it is not useful in predicting 
which patients in an early stage are likely to have an aggressive form of the 
disease and a short survival rate.  P53 deletion, ATM deletion or mutation have 
been described to influence CLL prognosis and clinical response to DNA- 
damaging agents (Pleyer, Egle et al. 2009). 
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1.11 Bcl-2 family interaction with non Bcl-2 family proteins 
     The anti-apoptotic Bcl-2 proteins have been reported to regulate another aspect 
of cell death. Bcl-2 and Bcl-xl have been linked to autophagy. Autophagy is a 
nonapoptotic cell death that is found to be suppressed by Bcl-2 and Bcl-xl 
(Shimizu, Kanaseki et al. 2004). These proteins can bind to the tumor suppressor 
beclin 1 (BECN1), which contains a BH3 domain, to  inhibit autophagosome 
formation (Oberstein, Jeffrey et al. 2007).  ATG12, which is an autophagic 
protein, was recently reported to have a unique BH3-like motif that mediates 
binding and inactivates the anti-apoptotic activity of Bcl-2 and Mcl-1 (Rubinstein, 
Eisenstein et al. 2011). 
     The Bcl-2 proteins usually interact through the BH3 domain; however, 
proteins without a distinct BH3 domain can interact with the Bcl-2 family. This 
suggest that a BH3 domain may not be required to engage the Bcl-2 family 
interaction where molecules containing a  BH3-like domain may also mediate this 
function (Chipuk, Moldoveanu et al. 2010). For example, cytosolic p53 has been 
reported to interact with anti-apoptotic Bcl-2 protein and/or Bak and Bax. 
Following genotoxic stress, p53 can promote apoptosis by localizing into the 
mitochondria (Marchenko, Zaika et al. 2000). It has been shown that p53 is 
sequestered by Bcl-xl in the cytosol, and this interaction can be disrupted by 
Puma following genotoxic stress (Chipuk, Bouchier-Hayes et al. 2005). Recently, 
three conserved hydrophobic residues (F19, W23 and L26) of p53 (SN15) peptide 
have been identified to anchor into three hydrophobic pockets of Bcl-xl in a 
similar manner as the BH3 peptide (Bharatham, Chi et al. 2011). 
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CHAPTER II  
AN ANTI-APOPTOTIC BCL-2 FAMILY EXPRESSION INDEX 
PREDICTS THE RESPONSE OF CHRONIC LYMPHOCYTIC 
LEUKEMIA TO ABT-737 
Sayer Al-harbi et al, BLOOD, 29 SEPTEMBER 2011, VOLUME 118, 
 NUMBER 13  
2.1 Abstract 
     The anti-apoptotic Bcl-2 proteins regulate lymphocyte survival and are 
overexpressed in lymphoid malignancies, including CLL. The small molecule 
inhibitor ABT-737 binds with high affinity to Bcl-2, Bcl-xl, and Bcl-w but with 
low affinity to Mcl-1, Bfl-1, and Bcl-b. The active analog of ABT-737, navitoclax 
has shown a high therapeutic index in lymphoid malignancies; developing a 
predictive marker for it would be clinically valuable for patient selection or choice 
of drug combinations. Here we used RT-PCR as a highly sensitive and 
quantitative assay to compare expression of anti-apoptotic Bcl-2 genes that are 
known to be targeted by ABT-737. Our findings reveal that the relative ratio of 
Mcl-1 and Bfl-1 to Bcl-2 expression provides a highly significant linear 
correlation with ABT-737 sensitivity (r=0.6, P<0.001). In contrast, anti-apoptotic 
transcript levels, used individually or in combination for high or low affinity 
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ABT-737-binding proteins could not predict ABT-737 sensitivity. The (Mcl-1 + 
Bfl-1)/Bcl-2 ratio was validated in a panel of leukemic cell lines subjected to 
genetic and pharmacologic manipulations. Changes following ABT-737 treatment 
included increased expression of Bfl-1 and Bcl-b that may contribute to treatment 
resistance. This study defines a highly significant Bcl-2 expression index for 
predicting the response of CLL to ABT-737.
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2.2 Introduction 
     Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in 
the Western World (Lee, Dixon et al. 1987). It is characterized by an expansion of 
small mature B cells in the peripheral blood, lymph nodes, and bone marrow. The 
standard of care for medically-fit patients involves sequential cycles of chemo-
immunotherapy with the purine nucleoside analog fludarabine combined with 
cyclophosphamide and the anti-CD20 monoclonal antibody rituximab (FCR) 
(Hallek, Fischer et al. 2010; Robak, Dmoszynska et al. 2010).  
     The Bcl-2 family proteins regulate apoptosis primarily at the mitochondria 
through the intrinsic apoptotic pathway (Del Gaizo Moore, Brown et al. 2007; 
Letai 2008). These proteins are divided into three classes based on sequence 
homology (Bcl-2 homology domains BH1 to BH4) and function (Adams and 
Cory 2007; Deng, Carlson et al. 2007). The anti-apoptotic proteins that display 
sequence homology in all BH1-BH4 domains are Bcl-2, Bcl-xl, Bcl-w, Mcl-1, 
Bfl-1, and Bcl-b. The pro-apoptotic Bcl-2 family members are divided into 
multidomain effectors (Bax and Bak containing BH1-BH3 domains) and the 
BH3-only proteins (Bim, Puma, and Noxa). Increased expression of the anti-
apoptotic proteins represents the main factor that accounts for blocking the 
intrinsic apoptosis pathway. This inhibition of apoptosis is accomplished by 
sequestering pro-apoptotic proteins and thus preventing mitochondrial outer 
membrane permeabilization (MOMP) (Tait and Green 2010), (Cheng, Wei et al. 
2001; Willis, Chen et al. 2005; Certo, Del Gaizo Moore et al. 2006).  
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     Elevated levels of Bcl-2, Mcl-1, and Bcl-xl mRNA and protein are found in 
many solid tumors and hematologic malignancies, including CLL (Gottardi, 
Alfarano et al. 1996; Kitada, Andersen et al. 1998; Pepper, Hoy et al. 1998; Rust, 
Harms et al. 2005; Stam, Den Boer et al. 2010). Importantly, Bcl-2 and Mcl-1 
protein expression parallels their mRNA levels in diffuse large B-cell lymphoma 
(DLBCL) and CLL (Shen, Iqbal et al. 2004; Veronese, Tournilhac et al. 2008). In 
most cases of follicular lymphoma, high Bcl-2 levels could be caused by 
chromosomal translocation t(14;18), which places the Bcl-2 gene under the 
control of the IgH enhancer, leading to overproduction of the Bcl-2 transcript and 
protein (Tsujimoto, Finger et al. 1984). In CLL, loss of microRNAs (miR) is 
involved in regulation of the Bcl-2 family expression levels. 13q14 is the most 
commonly detected chromosomal deletion in CLL that leads to loss of miR-15a 
and miR-16, which causes increased Bcl-2 levels (Cimmino, Calin et al. 2005). In 
addition, Mcl-1 can also be regulated by miRs, as miR-29 is known to negatively 
regulate Mcl-1 levels (Calin, Ferracin et al. 2005). Several reports suggest that 
Bcl-2 family proteins can be used as a predictive marker for the CLL response to 
chemotherapy. The Mcl-1/Bax ratio was reported to correlate with chemo-
resistance to fludarabine and rituximab (Bannerji, Kitada et al. 2003; Pepper, Lin 
et al. 2008). The Bcl-2/Bax ratio was also associated with resistance to 
chlorambucil (Williamson, Kelly et al. 1998). In addition, Bcl-xl levels were 
found to correlate with resistance to many standard chemotherapeutic agents in 
the 60-tumor cell line NCI panel (Amundson, Myers et al. 2000). 
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     ABT-737 was developed as a rationally-designed, small-molecule inhibitor 
that binds with high affinity to Bcl-2, Bcl-xl, and Bcl-w but with much lower 
affinity to Mcl-1, Bfl-1, and Bcl-b (Oltersdorf, Elmore et al. 2005). The orally 
available Bcl-2-family inhibitor navitoclax (ABT-263) is now in clinical 
development for lymphoid malignancies, including CLL, both as a single agent 
and in combination with chemotherapy and/or monoclonal antibodies (Oltersdorf, 
Elmore et al. 2005). Navitoclax showed a high therapeutic index in drug-resistant 
lymphoid malignancies with low incidence of off-target toxic effects in a phase 1 
dose-escalation study (Wilson, O'Connor et al. 2010). Moreover, preliminary 
efficacy data from a phase I study with navitoclax (ABT-263) in patients with 
small cell lung carcinoma (SCLC) and other solid tumors are encouraging as they 
show that the drug is safe and well-tollerated (Gandhi, Camidge et al. 2011). 
ABT-737 induces apoptosis in primary follicular lymphoma, CLL, acute myeloid 
leukemia, and solid tumor cells (Oltersdorf, Elmore et al. 2005; Konopleva, 
Contractor et al. 2006; Del Gaizo Moore, Brown et al. 2007). Interestingly, tumor 
cell lines tested for ABT-737 response in cell culture have shown similar activity 
in xenografts derived from the same cell lines in vivo (Oltersdorf, Elmore et al. 
2005; Hann, Daniel et al. 2008).  
     Sensitivity to ABT-737 is thought to depend on a Bcl-2 complex enriched for 
Bim (Del Gaizo Moore, Brown et al. 2007; Deng, Carlson et al. 2007). High 
levels of Mcl-1 were also suggested to account for ABT-737 resistance mostly 
based on cell line studies (Konopleva, Contractor et al. 2006; van Delft, Wei et al. 
2006; Chen, Dai et al. 2007). In contrast, other studies report that there is no 
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correlation between Mcl-1 expression and the response to ABT-737 in primary 
CLL and in acute lymphoblastic leukemia xenografts (Del Gaizo Moore, Brown 
et al. 2007; Mason, Khaw et al. 2009; Vogler, Butterworth et al. 2009; High, 
Szymanska et al. 2010). Moreover, the ratios of Bcl-2/Bim, Bcl-2/Bax, Mcl-
1/Bim, or Mcl-1/Bax could not predict sensitivity to ABT-737 in primary CLL 
(Mason, Khaw et al. 2009). Interestingly, long-term exposure to ABT-737 
resulted in increased levels of both RNA and protein levels of Mcl-1 and Bfl-1 
and development of resistance in lymphoma cell lines that were initially sensitive 
(Yecies, Carlson et al. 2010). 
     There are currently no satisfactory predictive markers for the wide range of 
response to ABT-737 in primary lymphoid cells. Developing a predictive index 
for ABT-737 response may help in patient selection or choice of drug 
combinations. In this study we examined whether quantifying expression of all 
anti-apoptotic Bcl-2 family transcripts whose encoded proteins are known to be 
targeted by ABT-737 could be used to identify a gene expression index that 
predicts ABT-737 sensitivity. Here, we used a highly sensitive and quantitative 
real-time (RT-PCR) assay to examine expression of six anti-apoptotic Bcl-2 
family genes. We defined the relative expression of (Mcl-1 + Bfl-1)/Bcl-2 as the 
most significant predictive marker for the response of primary CLL and leukemic 
cell lines to ABT-737 treatment. 
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2.3 Methods 
2.3.1 Cell culture 
     Peripheral blood samples from 57 patients with CLL and six healthy donors 
were obtained with the patients’ informed consent according to protocols 
approved by the institutional review board (IRB) according to the Declaration of 
Helsinki. All primary CLL cells were freshly processed without freezing. 
Lymphocytes were purified by Ficoll-Paque PLUS (Amersham Biosciences, 
Piscataway, NJ) gradient centrifugation. Cells were washed twice in media and 
cultured at a density of 1 х 106 cells/ml in RPMI-1640 medium supplemented 
with 5% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), L-
glutamine (Invitrogen, Carlsbad, CA), and 100 units/ml penicillin-streptomycin 
(Gibco BRL, Gaithersburg, MD). Primary CLL cells were treated for 18 hours 
with ABT-737 at 50 nM, a concentration previously shown to be effective in most 
primary CLL patients tested (Mason, Khaw et al. 2009). Nine leukemic cell lines 
were used in the study: (i) three CLL (Mec-1, Mec-2, and PTA-3920), (ii) two 
Pre-B (Nalm-6 and Reh), two B-cell-derived (NCI-H929 and IM-9), and two T-
cell-derived (Jurkat and Molt-4). These cell lines were obtained from the 
American Type Culture Collection (ATCC; Manassas, VA), with the exception of 
Mec-1 and Mec-2, which were a gift from Dr. Y. Saunthararajah (Cleveland 
Clinic). The cell lines, CLL primary cells, and human lymphocytes obtained from 
healthy donors were all cultured under similar conditions. ABT-737 was obtained 
from Abbott Laboratories (Abbott Park, IL).  
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2.3.2 Purification of lymphocytes from healthy donors 
     Highly purified lymphocytes were obtained using the Gambro Elutra
TM
 Cell 
Separation System. Following the apheresis procedure, cells were washed in a 
saline/tricitrasol solution prior to elutriation. Cell composition was verified on 
Cell Dyn 3700 (Abbott Diagnostics, Abbott Park, IL) prior to elutriation.  Cells 
were separated using a continuous countercurrent buffer flow of Hank’s Balanced 
Salt Solution (Lonza BioWhittaker, Switzerland), with simultaneous 
centrifugation, using the Caridian Elutra Cell Separation System (CaridianBCT, 
Lakewood, CO).  Fractions were centrifuged at 2500 rpm for 5 min at 4C° and 
pooled to concentrate the product.  Purity of the final combined product as 
determined on the Cell Dyn 3700 was >97%.  
 
2.3.3 Flow cytometry 
     Cell death was assessed by phosphatidylserine (PS) externalization as we have 
previously described (Chen, Gong et al. 2001). After 18 hours of culture, primary 
CLL cells and established cell lines were stained with fluorescein-conjugated 
Annexin V (BD Biosciences, San Jose, CA) and propidium iodide (PI) and 
analyzed on a BD FACSCalibur flow cytometer. Raw data were analyzed using 
the CellQuest software. Results were normalized to survival of untreated cells. 
Spontaneous cell death in freshly derived CLL cells was less than 30%.   
Flow cytometric immunophenotyping was performed at Cleveland Clinic as part 
of the diagnostic evaluation on a FACSCanto instrument (BD Biosciences, San 
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Jose, CA). Each of these flow cytometric evaluations was performed using 
fluorescently labeled monoclonal antibodies against CD38 and ZAP70. Staining 
protocols were standard lyses/washing protocols, as previously described (Chen, 
Gong et al. 2001). 
 
2.3.4 FISH 
     A dual-color probe for CLL PANEL 1 (ATM/p53) and a tri-color probe for 
CLL PANEL 2 (D13S319/13q34/CEP12), (Abbott Molecular, Inc., Des Plaines, 
IL) were used. Fluorescence in situ hybridization (FISH) was performed 
according to the manufacturer’s instructions. The p53 probe corresponds to 
chromosomal region 17p13.1. The ATM probe corresponds to chromosome 
region 11q22.3. Chromosomal region 13q34 was detected by the D13S319 probe. 
Trisomy of chromosome 12 was detected by the CEP12 probe. Abnormalities of 
17p present in ≥ 15% of nucleated cells were considered positive. Abnormalities 
of other probes (13q34, CEP12, and ATM) present in ≥ 10% of nucleated cells 
were considered positive. 
 
2.3.5 Pharmacologic and genetic manipulation of Mcl-1 and Bfl-1 
     Flavopiridol was obtained from Sanofi-Aventis though the NCI Cancer 
Therapy Evaluation Program. All the ABT-737-resistant cell lines: Mec-1, Mec-2, 
PTA-3920, NCI-H929, and Nalm-6 were treated with flavopiridol for 4 hours 
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with a 300 nM concentration, which was reported to be effective in decreasing 
Mcl-1 levels (Yecies, Carlson et al. 2010). After the drug was removed, cells were 
then treated with 100 nM of ABT-737 (EC50 of sensitive cell lines) for 18 hours.  
     Mcl-1 and Bfl-1 knockdown in Mec-1 cells was achieved by shRNAs 
delivered with the use of lentiviral-mediated transduction. Cell populations with 
stable expression of shMcl-1, shBfl-1, and as control a scrambled shRNA 
(shControl) were selected by puromycin (Sigma). Lentiviral particles targeting 
three different regions of Mcl-1 (sc-35877-V), and Bfl-1 (sc-37285-V), and the 
scrambled shRNA (sc-108080) were obtained from Santa Cruz, CA.  
 
2.3.6 RNA isolation and quantitative RT-PCR 
     Total RNA was isolated using the Trizol method (Invitrogen). Two µg of RNA 
were reverse transcribed using the TaqMan reverse transcription kit and amplified 
using the SYBR Green Master Mix (Applied Biosystems, N8080234 and 
4309155) and examined on a 7500 Real-Time PCR system (Applied Biosystems). 
Quantitative, real-time reverse transcription polymerase chain reaction (RT-PCR) 
was performed as we have described previously (Crosby, Jacobberger et al. 2007) 
using the following specific primers: Bcl-B: 5’-GCTGGGATGGCTTTTGTCA-3’ 
(forward) and 5’- GCCTGGACCAGCTGTTTTCTC-3’ (reverse); Bcl-w: 5’-
ACCCCAGGCTCAGCCCAACA-3’ (forward) and 5’-
CAGCACACAGTGCAGCCCCA-3’ (reverse); Bcl-2 (Stecca, Mas et al. 2007): 
5’-GGAGGATTGTGGCCTTCTTT-3’ (forward) and 5’-
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GGAGGATTGTGGCCTTCTTT-3’ (reverse); Bcl-xl (Aerbajinai, Giattina et al. 
2003): 5’-GGATGGCCACTTACCTGA-3’ (forward) and 5’-
GCCGTACAGTTCCACAAAGG-3’ (reverse); Bfl-1 (Yecies, Carlson et al. 
2010): 5’-TTACAGGCTGGCTCAGGACT-3’ (forward) and 5’-
AGCACTCTGGACGTTTTGCT-3’ (reverse); Mcl-1 (Yecies, Carlson et al. 
2010): ATGCTTCGGAAACTGGACAT-3’ (forward) and 5’-
TCCTGATGCCACCTTCTAGG-3’ (reverse); Bim (Nordigarden, Kraft et al. 
2009): 5’-TGGCAAAGCAACCTTCTGATG-3’ (forward) and 5’-
GCAGGCTGCAATTGTCTACCT-3’ (reverse); Noxa (Jiang, Lucas et al. 2008): 
5’-TGGAAGTCGAGTGTGCTACTCAA-3’ (forward) and  
5’-CAGAAGAGTTTGGATATCAGATTCAGA-3’ (reverse); Puma (Jiang, 
Lucas et al. 2008): 5’-GCATGCCTGCCTCACCTT-3’ (forward) and 5’-
TCACACGTCGCTCTCTCTAAACC-3’ (reverse); Actin (Yecies, Carlson et al. 
2010): 5’-AGAAAATCTGGCACCACACC-3’ (forward) and 5’-
AGAGGCGTACAGGGATAGCA-3’ (reverse). Each experiment was repeated 
twice. The Bcl-b and Bcl-w primers were designed using the Primer Express 
(Applied Biosystems), and Primer 3 (LIST sequence) software, respectively. A 
lymphocyte sample set was used to establish a baseline comparison between 
mRNA levels in CLL and healthy donors. The extent of knockdown of Mcl-1 and 
Bfl-1 levels was determined by quantitative RT-PCR using the above primers as 
well as those suggested by the manufacturer (Santa Cruz, CA) for Mcl-1 (sc-
35877-PR) and Bfl-1 (sc-37285-PR).  
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2.3.7 Statistical analysis 
     Baseline characteristics were grouped by in vitro culture sensitivity to ABT-
737 treatment and compared between the resulting two groups using Fisher’s 
exact test or t-test. Spearman correlation was used to assess the strength and 
direction of association between post-treatment cell viability and each Bcl-2 
family member individually or in combination. The Cohen interpretation of 
correlation (r) indicates that when r<0.3 it represents weak correlation, 0.3-0.5 is 
moderate, and >0.5 is strong. Three groups were defined based on cell viability. 
Expression of Bcl-2 family members, individually or in combination were 
compared among the three groups using the Kruskal-Wallis test. Pairwise 
comparisons between groups were performed using the Wilcoxon rank sum test.  
A Bonferroni correction was used for pairwise comparisons. Pre- to post-
treatment changes in Bcl-2 family transcripts were assessed using the Wilcoxon 
signed rank test. All statistical tests were two-sided. For pairwise comparisons, 
p<0.017 was used to indicate statistical significance. For all other comparisons, 
p<0.05 was used to indicate statistical significance. 
 
 
 
 
 
 41 
2.4 Results 
2.4.1 Primary CLL cells display differential sensitivity to ABT-737 
     To determine the sensitivity of CLL to ABT-737, freshly isolated primary CLL 
cells derived from the peripheral blood of patients were examined by flow 
cytometry for Annexin V staining as a cell death assay (Chen, Gong et al. 2001). 
The majority of primary CLL samples underwent apoptosis after treatment with 
ABT-737; however, there was a wide range of sensitivity, in agreement with 
earlier reports (Figure 2.1A) (Oltersdorf, Elmore et al. 2005; Mason, Khaw et al. 
2009). Based on their response, primary CLL samples from 57 patients could be 
classified into three groups: (i) A sensitive group (33/57 cases, 57.8%) with cell 
viability less than 40%, (ii) An intermediate group (15/57, 26.3%) with viability 
of 40-65%, and (iii) A resistant group (9/57, 15.7%) with viability > 65%. 
Increasing the time exposures of ABT-737 from 18 to 36 hours did not change the 
sensitivity groups for the CLL samples (data not shown). 
 
2.4.2 Baseline characteristics of patients with ABT-737 sensitive and resistant 
CLL are similar 
     Baseline characteristics of CLL patients in this study (Table 2.1, Figure 2.2A-
B) were grouped by in vitro culture sensitivity to ABT-737 treatment. The median 
age was similar for both groups. The majority of patients in both the ABT-737 
sensitive and resistant groups had early stage (Rai 0, I, or II) disease and had not 
been treated for their CLL prior to ABT-737 testing. The proportion of cases 
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positive for ZAP70 and CD38 by flow cytometry and commonly detected 
chromosomal abnormalities by fluorescence in situ hybridization (FISH) testing 
that are indicated do not differ significantly between the ABT-737 sensitive and 
resistant groups. ABT-737 sensitivity was similar for patients with early versus 
advanced stage of the disease (P = 0.7) (Figure 2.2A). It was also similar for 
common prognostic markers for CLL, such as ZAP70 (P = 0.72) or CD38 (P = 
0.54) expression (Del Poeta, Maurillo et al. 2001; Rassenti, Huynh et al. 2004) 
(Figure 2.2B), prior treatment, 17p deletion (p53) (Dohner, Stilgenbauer et al. 
2000; Seiler, Dohner et al. 2006), or 13q14 deletion (Table 2.1), consistent with 
previous findings (Del Gaizo Moore, Brown et al. 2007; Mason, Khaw et al. 
2009; Vogler, Butterworth et al. 2009). 
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Table 2.1: Patients characteristics 
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Figure 2.1.  A wide-range of responses to ABT-737 in primary CLL.  Primary 
CLL cells derived from 57 patients were incubated with ABT-737 (50 nM) for 18 
hours. Cell survival was assessed by Annexin V/FITC binding, as determined by 
flow cytometric analysis. Values are normalized to survival of untreated cells and 
each data point represents one CLL patient. Based on cell viability data, the 
response to ABT-737 was classified into: resistant (> 65%), intermediate (40% to 
65%), and sensitive (< 40%). 
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Figure 2.2. Responses to ABT-737 in primary CLL is independent of known 
prognostic markers. The proportion of CLL patients in the resistant/intermediate 
and sensitive groups respectively was examined with regard to the common CLL 
prognostic markers: (A) Rai stage and (B) ZAP70, CD38 expression. P-values are 
shown for comparison of groups. 
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2.4.3 Lack of correlation between expression of Bcl-2 family members, 
individually or combined, and their response to ABT-737 
     To investigate the possible contribution of Bcl-2 family members to ABT-737 
response, we determined their expression levels. Of the nine Bcl-2 family 
members that we have examined, we focused first on the six anti-apoptotic 
members since ABT-737 was designed to target anti-apoptotic proteins and we 
reasoned that their differential expression could define ABT-737 sensitivity. 
Expression of each individual anti-apoptotic transcript or their combinations in 
untreated CLL was plotted against cell viability following ABT-737 treatment 
(Figure 2.3). No linear correlation was found between expression levels of any 
single anti-apoptotic Bcl-2 family member (r < 0.3, P > 0.05) or their 
combination (r < 0.3, P > 0.05), considering those with either high affinity (Bcl-2, 
Bcl-w, and Bcl-xl) or those with low affinity (Mcl-1, Bfl-1, and Mc-1) to ABT-
737 (Figure 2.3). Next, we examined the expression of pro-apoptotic BH3-only 
Bcl-2 family members Noxa, Bim, and Puma. Their mRNA levels were relatively 
high in most of the tested CLL (data not shown). Nevertheless, no significant 
correlation was found between expression levels of any of these pro-apoptotic 
Bcl-2 family members, taken individually (r < 0.3, P > 0.05) or in combination (r 
< 0.3, P > 0.05) and ABT-737 sensitivity.   
     Moreover, the six mRNAs were expressed at relatively similar levels in all the 
healthy donors when they normalized to each other (Figure 2.4A). However, 
normalizing all anti-apoptotic Bcl-2 family to β-actin revealed that Mcl-1 levels 
were more abundant in normal lymphocytes compared to Bfl-1, Bcl-b, and Bcl-w, 
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which were expressed at very low levels ((Figure 2.4b), note logarithmic scale 
used to accommodate these large differences). In contrast, Bcl-b, Bfl-1, and Bcl-w 
were highly upregulated compared to Mcl-1 in primary CLL.  
 48 
 
 49 
Figure 2.3. Lack of correlation between mRNA expressions of anti-apoptotic 
Bcl-2 family members, individually or combined, and response to ABT-737. 
Quantitative RT-PCR was used to study anti-apoptotic Bcl-2 family mRNAs. 
Expression values of each anti-apoptotic transcript or their combinations were 
plotted against cell viability following ABT-737 treatment. RNA expression for 
each transcript was normalized to that obtained in lymphocytes isolated from six 
healthy donors. (A) Bcl-2, (B) Mcl-1, (C) Bfl-1, (D) Bcl-b, (E) Bcl-xl, (F) Bcl-w, 
(G) Bcl-2 + Bcl-xl + Bcl-w, and (H) Mcl-1 + Bfl-1 + Bcl-b expression. Spearman 
correlation (r) and P-values are shown. 
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2.4.4 An anti-apoptotic Bcl-2 family index predicts ABT-737 sensitivity  
     Because each anti-apoptotic transcript was expressed at different basal levels 
in the lymphocytes from healthy donors (Figure 2.4B), we next standardized the 
expression of the six mRNAs to one basal level to provide a better method of 
comparison in CLL cells. Normalization to β-actin revealed the most abundant 
anti-apoptotic determinants in untreated primary CLL (Figure 2.5). This approach 
guided us to identify the critical determinants of the ABT-737 sensitivity. The 
expression levels of Mcl-1, Bcl-2, and Bfl-1 were much higher compared to those 
of Bcl-xl and Bcl-w. The sensitive group had the highest levels of Bcl-2 as 
compared to expression of Mcl-1 and Bfl-1. The index mean was 0.45 for Bcl-2, 
0.40 for Mcl-1, and 0.21 for Bfl-1. In contrast, compared to Bcl-2, the 
intermediate group had relatively higher levels of Mcl-1 and Bfl-1, while the 
resistant group had much higher levels of Mcl-1 and Bfl-1. In the intermediate 
group, the index mean was 0.25 for Bcl-2, 0.37 for Mcl-1, and 0.21 for Bfl-1. In 
the resistant group, the index mean was 0.21 for Bcl-2, 0.48 for Mcl-1, and 0.19 
for Bfl-1. Next, we examined the expression of pro-apoptotic BH3-only Bcl-2 
family members Noxa, Bim, and Puma. Noxa levels were the highest compared to 
those of Bim and Puma in the CLL samples examined (data not shown). Thus 
Noxa levels were 3.5 and 6 fold higher than those of Bim and Puma, respectively 
(data not shown). 
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Figure 2.4. Bcl-2 family mRNA expression in lymphocytes isolated from 
healthy donors. (A) mRNA levels of Bcl-2 family members determined by 
quantitative RT-PCR normalized to those of the first healthy donor show similar 
expression for each Bcl-2 family transcript. (B) Bcl-2 family members have 
different basal levels normalized to β-actin. Note the logarithmic scale used to 
reveal the large differences in the expression levels. 
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Figure 2.5. Anti-apoptotic Bcl-2 family mRNA levels in ABT-737 sensitive, 
intermediate, and resistant CLL groups. RNA expression of anti-apoptotic Bcl-
2 family members, as determined by quantitative RT-PCR, was normalized to β-
actin for each CLL patient sample. Bcl-2, Mcl-1, and Bfl-1 levels were more 
abundant than those of Bcl-b, Bcl-xl, and Bcl-w in primary CLL. (A) The 
sensitive group. (B) The intermediate group. (C) The resistant group. Mean values 
are shown. 
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     In order to define an anti-apoptotic gene expression index predictive of ABT-
737 sensitivity, we plotted several combinations of genes relative to cell viability. 
The relative ratio of Mcl-1 and Bfl-1 to Bcl-2 expression provided the best linear 
correlation with ABT-737 sensitivity (r = 0.6, P < 0.001) (Figure 2.6A). By 
comparison, the relative ratios of Mcl-1/Bcl-2 (Figure 2.6B) or Bfl-1/Bcl-2 
(Figure 2.6C) showed a less robust linear correlation: (r = 0.45, P < 0.001), (r = 
0.28, P= 0.030), respectively. The relative ratio of Bcl-b/Bcl-2 (Figure 2.6D) 
showed no significant correlation (r = 0.16, P = 0.22). Including Bcl-b, Bcl-xl, 
(Figure 2.6E-F), or Bcl-w (data not shown) into the (Mcl-1 + Bfl-1)/Bcl-2 model 
had no significant effect on this correlation. The different ratios of anti-apoptotic 
Bcl-2 family mRNAs were determined in the resistant, intermediate, and sensitive 
groups (Figure 2.7). Of the different anti-apoptotic Bcl-2 family combinations 
evaluated, (Mcl-1 + Bfl-1)/Bcl-2 provided the highest predictive value for the 
ABT-737 response in CLL (Figure 2.7A), with P < 0.001 among all the three 
groups. In the sensitive class (average cell viability 26.2%), the average ratio of 
(Mcl-1 + Bfl-1)/Bcl-2 was 1.67. For the intermediate class (average cell viability 
53.5%), the average ratio was 2.3. In the resistant class (average cell viability, 
76.3), the average ratio was 3.3 (Table 2.2). 
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Table 2.2: The (Mcl-1/Bfl-1)/Bcl-2 index in CLL and SCLC cell lines 
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Figure 2.6. (Mcl-1 + Bfl-1)/Bcl-2 provides the most significant linear 
correlation for sensitivity to ABT-737. Cell viability after ABT-737 treatment 
was plotted against: (A) (Mcl-1+Bfl-1)/Bcl-2, (B) Mcl-1/Bcl-2, (C) Bfl-1/Bcl-2, 
(D) Bcl-b/Bcl-2, (E) (Mcl-1 + Bfl-1 + Bcl-b)/Bcl-2, and  (F) (Mcl-1+Bfl-
1)/(Bcl2+Bcl-xl) ratios. Spearman correlation (r) and P-values are shown. 
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Figure 2.7. The relative ratio of (Mcl-1 + Bfl-1)/Bcl-2 represents the most 
informative predictive marker for the ABT-737 sensitivity. Relative 
expression values for: (A) (Mcl-1 + Bfl-1) / Bcl-2, (B) Mcl-1/Bc-l2, (C) Bfl-
1/Bcl-2,  (D) Bcl-b / Bcl-2, (E) (Mcl-1 + Bfl-1 + Bcl-b)/Bcl-2, and (F) (Mcl-1 + 
Bfl-1)/(Bcl-2 + Bcl-xl), (Mcl-1 + Bfl-1)/Bcl-2 are the most significant among the 
sensitive, intermediate, and resistant groups. P-values are indicated for 
comparison between groups. 
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2.4.5 The (Mcl-1 + Bfl-1) / Bcl-2 ratio is predictive of ABT-737 response in 
leukemic and lung carcinoma cells 
     To further address the generality of our predictive model in leukemic cells, the 
(Mcl-1 + Bfl-1) / Bcl-2 ratio was determined in a panel of leukemic tumor cell 
lines (Table 2.3), (Figure 2.8). Of the nine cell lines tested, five (NCI-H929, 
Nalm-6, Mec-1, Mec-2, and PTA-3920) were most resistant to ABT-737. They all 
had a very high (Mcl-1 + Bfl-1) / Bcl-2 ratio, ranging from 6.4 to 17.5, with EC50 
> 1000 nM. Two other cell lines, Reh and Molt-4 displayed an intermediate 
sensitivity to ABT-737 (EC50= 300 and 400) having a ratio of 2.5 and 2.3, 
respectively. IM-9 and Jurkat were the most sensitive (EC50 ≤100 nM) and had 
ratios of 1.2 and 1.8, respectively (Table 2.3). These data indicate that the (Mcl-1 
+ Bfl-1) / Bcl-2 ratio is predictive for the ABT-737 response in a broad range of 
leukemic tumor cells, both primary and established. 
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Table 2.3: The (Mcl-1 + Bfl-1) / Bcl-2 ratio in leukemic cell lines 
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Figure 2.8. Relative expression of Bcl-2, Mcl-1, and Bfl-1 in a panel of 
leukemic cell lines. Bcl-2, Mcl-1, and Bfl-1 mRNA expression relative to β-actin 
in (A) NCI-H929, (B) Nalm-6, (C) Mec-1, (D) Mec-2, (E) PTA-3920, (F) Reh, 
(G) Molt-4, (H) Jurkat, and (I) IM-9 cells. 
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     Next, we tested if our model can also be applied to cancer types other than of 
hematological origin. Small cell lung carcinoma (SCLC) is a solid tumor that has 
been reported to have a high expression level of anti-apoptotic proteins, such as 
Bcl-2. As navitoclax (ABT-263) is evaluated in clinical trials in SCLC patients, 
we reasoned that it would be informative to test whether our model can predict 
ABT-737 response in SCLC cell lines. By using ONCOMINE (Rhodes, Yu et al. 
2004) as a cancer microarray database aimed to facilitate discovery from genome-
wide expression analyses, we applied our model in SCLC cell lines previously 
categorized as ABT-737 resistant, intermediate, and sensitive groups (Olejniczak, 
Van Sant et al. 2007). We found that in the sensitive group the average ratio of 
Mcl-1 and Bfl-1 to Bcl-2 was 1.7, with the intermediate and resistant groups 
having a ratio of 2.1 and 2.8, respectively (Table 2.2). Interestingly, these ratios 
were very close and consistent with our findings in CLL patients. Of the different 
anti-apoptotic Bcl-2 family combinations evaluated, the (Mcl-1 + Bfl-1) /Bcl-2 
ratio provided the highest predictive value for ABT-737 response in SCLC 
(r=0.73, P < 0.001) (Figure 2.9). 
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Figure 2.9. The (Mcl-1 + Bfl-1)/Bcl-2 represents the most significant linear 
correlation for sensitivity to ABT-737 in small cells lung carcinoma (SCLC). 
SCLC cell lines with a wide range of response (resistant, intermediate, and 
sensitive) to ABT-737 were plotted against: (A) (Mcl-1+Bfl-1)/Bcl-2, (B) Mcl-
1/Bcl-2, (C) Bcl-2, (D) (Mcl-1+Bfl-1)/(Bcl-2+Bcl-xl) ratios. Spearman 
correlation (r) and P-values are shown. The Olejniczak dataset was used as 
extracted from the ONCOMINE database (Rhodes, Yu et al. 2004). 
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2.4.6 Decreased Mcl-1 and/or Bfl-1 levels enhance ABT-737 response in 
resistant CLL cell lines  
     The five cell lines that we found to be highly resistant to ABT-737 had also a 
high ratio of Mcl-1 and Bfl-1 to Bcl-2. We examined whether a decrease in Mcl-1 
and/or Bfl-1 levels by a clinically relevant approach may improve ABT-737 
response in resistant cell lines. Flavopiridol, which as a CDK9 inhibitor was 
shown to decrease Mcl-1 at transcriptional level, also demonstrated a high 
response rate in a phase II clinical trials in relapsed CLL patients (Lin, Ruppert et 
al. 2009). All ABT-737 resistant cell lines were treated with flavopiridol and then 
the Bcl-2, Mcl-1, and Bfl-1 levels were determined by quantitative RT-PCR 
(Figure 2.10A; only data for CLL cell lines are shown). A four-hour flavopiridol 
treatment decreased Mcl-1 and Bfl-1 levels, with little effect on Bcl-2 levels. 
Following pre-treatment with flavopiridol, the (Mcl-1 + Bfl-1)/ Bcl-2 predictive 
index values changed in all five ABT-737 resistant cell lines, shifting from highly 
resistant to an index similar to what we have established for the sensitive CLL 
group (Table 2.4). To determined whether this shift of the (Mcl-1 + Bfl-1) / Bcl-2 
ratio by flavopiridol can convert the resistant cell lines to the sensitive group. 
Following flavopiridol pre-treatment and removal, cells were treated with ABT-
737 for 18 hours (Figure 2.10B). There was a significant increase in cell death 
when cells were pretreated with flavopiridol prior to ABT-737 treatment as 
compared to single treatments with ABT-737 or flavopiridol for 18 hours (data for 
NCI-H929 and Nalm-6 are not shown). 
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Figure 2.10. Flavopiridol decrease Mcl-1 and Bfl-1 levels and increase the 
response to ABT-737 in resistant CLL cell lines. (A) Mec-1, Mec-2, and PTA 
CLL cells were treated with flavopiridol for four hours and then Bcl-2, Mcl-1 and 
Bfl-1 levels were assessed by quantitative RT-PCR. (B) Mec-1, Mec-2 and PTA-
3920 were treated with flavopiridol for four hours, then the drug was removed and 
cells were cultured without or with ABT-737(100 nM) for an additional 18 hours. 
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Cell viability was assayed by annexin-V–FITC and PI staining and analyzed by 
flow cytometry. Values are normalized to untreated cells and DMSO treatment 
served as a negative control. P values were determined by the 2-tailed t-test. The 
graphs presented are representative of two independent experiments with data 
shown as mean   s.d. 
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Table 2.4. The (Mcl-1+Bfl-1)/Bcl-2 in ABT-737–resistant cell lines after 
treatment with flavopiridol for 4 hours. 
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     To further validate the pharmacologic inhibitor data, we applied a targeted 
genetic approach for reducing Mcl-1 or Bfl-1, using shRNAs transduced with 
lentivirus particles. Mec-1 was chosen since it is a highly ABT-737-resistant CLL 
cell line that has high Mcl-1 and Bfl-1 levels. Examining knockdown of Mcl-1 
and Bfl-1 by quantitative RT-PCR indicated an ~ 50% and 45% reduction in Mcl-
1 and Bfl-1 levels in shMcl-1 and shBfl-1-expressing Mec-1 cells, respectively 
(Figure 2.11A). Estimating the index in these two cell lines indicated that 
knockdown of Mcl-1 or Bfl-1 by shRNA reduced the index from 9.6 in parental 
cells to 3.4 in shMcl-1 and 3.8 in shBfl-1-expressing Mec-1 cells, respectively. 
Treating shMcl-1 and shBfl-1-expressing cells with ABT-737 increased cell death 
significantly as compared to parental Mec-1 cell or those expressing as a control 
scrambled shRNA (Figure 2.11B).  
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Figure 2.11. ShRNA decrease Mcl-1 and Bfl-1 levels and increase the 
response to ABT-737 in resistant CLL cell lines. (A) Quantitative RT-PCR 
analyses of Bcl-2, Mcl-1, and Bfl-1 levels in Mec-1 parental, shMcl-1, shBfl-1, 
and as a control, scrambled shRNA (shControl)-expressing cells. (B) Mec-1 
parental, shControl, shMcl-1, and shBfl-1-expressing cells were treated with 
ABT-737 (1000 nM) for 18 hours. Cell viability was assayed by annexin-V–FITC 
and PI staining and analyzed by flow cytometry. Values are normalized to 
untreated cells and DMSO treatment served as a negative control. P values were 
determined by the 2-tailed t-test. The graphs presented are representative of two 
independent experiments with data shown as mean   s.d. 
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2.4.7 Modulation of anti-apoptotic Bcl-2 family mRNA expression following 
ABT-737 treatment 
     As chemotherapeutics are known to modulate the expression of Bcl-2 family 
members in hematologic tumors, we next examined the changes in expression of 
anti-apoptotic Bcl-2 family mRNAs after ABT-737 treatment. In most primary 
CLL samples tested there was a significant decrease in Bcl-2 (P < 0.001) and 
Mcl-1 (P = 0.003) mRNA expression (Figure 2.12 A-B). In contrast, Bfl-1, Bcl-b, 
and Bcl-w expression levels were highly upregulated following ABT-737 
treatment (Figure 2.12 C-E). Bfl-1 levels were upregulated 9-fold, (P < 0.001), 
with Bcl-w levels increased 6.5-fold (P < 0.001). Bcl-b levels were increased 
more than 10-fold following ABT-737 treatment (P < 0.001). There were no 
significant changes in Bcl-xl levels (P = 0.26) (Figure 2.12 F). 
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Figure 2.12. Changes in the levels of anti-apoptotic Bcl-2 family transcripts 
following ABT-737 treatment. Changes in mRNA expression levels of anti-
apoptotic Bcl-2 family proteins after treatment with ABT-737 (50 nM) for 18 
hours. Expression was determined by quantitative RT-PCR to compare fold 
difference in expression to levels prior to treatment that were normalized to those 
found in lymphocytes isolated from six healthy donors. Fold change for: (A) Bcl-
2, (B) Mcl-1, (C) Bfl-1, (D) Bcl-b, (E) Bcl-w, and (F) Bcl-xl levels. P-values are 
shown. 
 72 
2.5 Discussion 
     ABT-737 was rationally designed to bind selectively to the anti-apoptotic 
proteins Bcl-2, Bcl-xl, and Bcl-w that are known to be overexpressed in lymphoid 
malignancies (Kitada, Andersen et al. 1998; Pepper, Hoy et al. 1998). There is no 
available marker that directly predicts the sensitivity to ABT-737 based on anti-
apoptotic protein expression levels. The inconsistency of reports on the 
correlation of the expression of anti-apoptotic proteins with the ABT-737 
response might be due to the difficulty in detecting some of them by Western 
blotting in primary cells (Del Gaizo Moore, Brown et al. 2007; Mason, Khaw et 
al. 2009; Vogler, Butterworth et al. 2009). This may explain the emphasis that has 
been placed on individual anti-apoptotic proteins, such as Bcl-2 and Mcl-1, with 
no extensive studies available on the contribution of Bfl-1 and Bcl-b to the ABT-
737 response in primary CLL. Moreover, the primary use of Western blotting in 
most of these studies further limited the development of quantitative approaches. 
 
     Here, we report that the anti-apoptotic Bcl-2 family mRNAs are expressed at 
different basal levels in lymphocytes from healthy donors. Therefore, comparing 
the basal expression levels of the anti-apoptotic transcripts in CLL to healthy 
donors could be misleading. In contrast, normalizing these mRNAs to β-actin 
provided an equal scale for comparison of their expression in untreated primary 
CLL and further establishes their contribution to the ABT-737 response. We 
found that Mcl-1, Bcl-2, Bfl-1, and Bcl-b transcripts were more abundant than 
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those of Bcl-xl and Bcl-w. However, Mcl-1, Bfl-1, and Bcl-2 appear to be the 
most critical anti-apoptotic factors that account for ABT-737 sensitivity. Applying 
RT-PCR as a highly sensitive and quantitative assay allowed us to establish a 
quantitative comparison between the expression levels of Bcl-2 family members. 
Bcl-2, Mcl-1, and Bfl-1 expression were higher in cells sensitive to ABT-737, 
with Bcl-2 expression being the highest. These findings may explain why the 
sensitivity to ABT-737 in primary CLL was correlated with high Mcl-1 levels in 
previous reports (Vogler, Butterworth et al. 2009).  
 
     In the moderately sensitive CLL group, Mcl-1 and Bfl-1 levels were higher 
than those of Bcl-2, whereas in the resistant group Mcl-1 and Bfl-1 expression 
were much higher compared to those of Bcl-2. Our findings reveal that individual 
or even combined levels of Mcl-1 and Bfl-1 could not predict ABT-737 
sensitivity without accounting for their relative ratio to Bcl-2. This likely reflects 
the molecular abundance of Mcl-1, Bfl-1, and Mcl-1, as well as the cellular 
balance between low and high affinity ABT-737-binding proteins. Importantly, 
our model directly addresses the wide range of ABT-737 responses in primary 
CLL that were reported previously (Oltersdorf, Elmore et al. 2005; Mason, Khaw 
et al. 2009). The anti-apoptotic Bcl-2 family expression index in a panel of 
leukemic tumor cell lines was consistent with our CLL data. This model was also 
validated in SCLC as another tumor type. Recent data from a phase I study of 
navitoclax (ABT-263) has shown that a high Bcl-2 copy number in circulating 
tumor cells was associated with the best tumor response in SCLC patients. 
 74 
Remarkably, our predictive model showed a higher correlation with ABT-737 
response than expression of Bcl-2 alone in these SCLC cell lines based on data 
extracted from the ONCOMINE database (Rhodes, Yu et al. 2004). There are 
currently 17 clinical trials (http://clinicaltrials.gov/, 06-13-2011) with the Bcl-2-
family inhibitor navitoclax, the oral derivative of ABT-737, for CLL, other 
hematologic malignancies, and solid tumors for which our predictive model could 
also become informative.  
 
     We also studied the expression of pro-apoptotic BH3-only Bcl-2 members 
Noxa, Bim, and Puma. These pro-apoptotic members are most likely to be 
sequestered by anti-apoptotic proteins as the primed for cell death model predicts 
(Deng, Carlson et al. 2007). This model posits that cells expressing significant 
amounts of BH3-only proteins, such as Bim, must sequester them with anti-
apoptotic proteins to stay alive. The sensitive CLL group had increased levels of 
Noxa, Bim, and Puma. However, as some resistant and intermediate groups also 
had high Noxa, Bim, and Puma levels, we could not establish a predictive value 
for a BH3-only index and ABT-737 response in the CLL samples we have 
examined. Nevertheless, it is possible that including their expression in a Bcl-2 
family index may help to predict clinical response to other therapeutics or in other 
tumor types.  
     We have applied both a clinically relevant pharmacologic (flavopiridol) as 
well as a genetic (shRNA) approach to reduce Mcl-1 and Bfl-1 levels to improve 
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the ABT-737 response in the resistant cell lines. shRNA-expressing cells, in 
which expression of either Mcl-1 or Bfl-1 was down regulated, were treated with 
a higher ABT-737 concentration as compared to flavopiridol in response to which 
both Mcl-1 and Bfl-1 levels were decreased. In addition, there was some 
compensation by an increase in the levels of alternative apoptosis-resistance 
determinants, Mcl-1 in shBfl-1 and Bfl-1 in shMcl-1-expressing cells. 
Nevertheless, these data indicate that clinical agents that reduce Mcl-1 and Bfl-1 
levels can be used in combination with navitoclax to maximize their efficacy. 
 
     Following ABT-737 treatment, we observed induction of Bfl-1, Bcl-b, and 
Bcl-w expression and reduction of Bcl-2 and Mcl-1 levels in most CLL samples. 
Bfl-1 and Bcl-b are known to have very low binding affinity for ABT-737; 
therefore, their increased levels suggests that these proteins may account for 
resistance as a result of long-term ABT-737 exposure, as a published report 
indicates (Yecies, Carlson et al. 2010). Here we show that Bfl-1 levels can be 
upregulated following ABT-737 treatment in primary CLL not only, as previously 
reported, as a result of co-culture of primary CLL with fibroblasts that mimics the 
lymph node environment (Vogler, Butterworth et al. 2009). As this is the first 
report that reveals the elevated Bcl-b levels following ABT-737 treatment, this 
finding suggests a potential novel role for Bcl-b in developing ABT-737 
resistance in CLL patients. 
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     In summary, we have applied RT-PCR as a highly sensitive and quantitative 
assay to examine Bcl-2 family transcripts in primary CLL to develop a unique 
predictive marker for ABT-737 sensitivity. Our model provides highly predictive 
power for ABT-737 sensitivity in primary CLL. This approach requires a small 
number of primary cells and allows the study of comparative expression of all 
relevant genes. It can also identify whether CLL patients are dependent on Mcl-
1/Bfl-1 or on Bcl-2 as Mcl-1-dependent leukemic cells have been reported to be 
more chemo-sensitive than those that are Bcl-2 dependent (Brunelle, Ryan et al. 
2009). Establishing this dependency may guide appropriate ABT-737 
administration for future development of novel combinations of ABT-737 with 
other targeted agents.  
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CHAPTER III 
BCL-XL EXPRESSION IS A MARKER OF SHORT TIME TO 
TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA 
Sayer Al-harbi et al. 
 
3.1 Abstract 
     Chronic lymphocytic leukemia (CLL) is the most common leukemia in the 
western world. Whereas some patients may require immediate therapy and 
survive only months, others may live indefinitely untreated. The heterogeneous 
clinical course of CLL indicates the need for a prognostic marker that can be used 
to predict disease progression and allow better management of the disease. 
Common prognostic markers, such as p53, ZAP70, and CD38 are useful in CLL, 
but they fail to predict clinical outcome in a substantial number of CLL patients 
and limited usefulness in guiding therapeutic decisions. The anti-apoptotic Bcl-2 
proteins are overexpressed in lymphoid malignancies, including chronic 
lymphocytic leukemia. While extensive studies have focused on the role of Bcl-2 
or Mcl-1 in CLL, nothing is known about the role of other anti-apoptotic proteins 
and their contribution to clinical outcome in CLL patients. Therefore, we used 
RT-PCR as a highly quantitative and sensitive assay to assess expression of all 
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known anti-apoptotic Bcl-2 family genes to study their contribution to treatment 
free survival in CLL. Our finding indicate that only high Bcl-xl expression is 
strongly correlate (P=0.002) with short treatment-free survival. Strikingly, Bcl-xl 
was able to identify patients with high risk in the ZAP70 negative and CD38 
negative groups as well as in patients with normal/unknown p53 showing a very 
powerful prognostic value in CLL. 
 
3.2 Introduction 
     Chronic lymphocytic leukemia (CLL) is the most common leukemia in the 
Western world (Lee, Dixon et al. 1987). CLL patients have very wide overall 
survival; whereas some patients may survive for months, others may live for 
many years (Zwiebel and Cheson 1998; Chiorazzi, Rai et al. 2005). This 
heterogonous clinical course led to the search for a prognostic marker that can 
predict disease progression. The identification of such markers would enable 
individualized counseling and better management of the disease. Immunoglobulin 
heavy chain variable-region (VH) gene mutation status and zeta-associated 
protein 70 (ZAP70) and CD38 have been proposed to be prognostic markers in 
CLL (Damle, Wasil et al. 1999; Hamblin, Davis et al. 1999; Orchard, Ibbotson et 
al. 2004; Rassenti, Huynh et al. 2004). Despite their clinical value, there are some 
technical difficulties involved in these markers such as labor intensive, 
standardization and modification following chemotherapy (Shanafelt, Byrd et al. 
2006; Van Bockstaele, Verhasselt et al. 2009).  In addition, p53 deletion (del 17p) 
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is a well-established marker associated with short survival and chemoresistance. 
However, p53 deletion accounts only for a small percentage of CLL patients 
(Dohner, Stilgenbauer et al. 2000; Bottcher, Ritgen et al. 2012); One study found 
the prevalence of p53 mutation in a large CLL cohort to be less than 8% of the 
cases (Zenz, Krober et al. 2008; Gonzalez, Martinez et al. 2011). Overall, these 
established prognostic markers fail to predict clinical outcome in a considerable 
number of CLL patients (Bottcher, Ritgen et al. 2012). Moreover, it is difficult to 
combine the results of these variables markers to asses the risk in individual 
patients (Shanafelt, Byrd et al. 2006). Thus, additional prognostic markers for 
CLL patients are of interest. 
 
     Blocked apoptosis is a hallmark of treatment-resistant cancers and thus, may 
highlight the potential application of Bcl-2 family members as prognostic markers 
(Letai 2008; Hanahan and Weinberg 2011). In fact, several studies have linked 
Bcl-2 family expression and response to chemotherapy in different type of 
cancers. It has been recently reported that patients with cancers highly primed to 
cross the apoptotic threshold exhibited superior clinical responses to 
chemotherapy (Ni Chonghaile, Sarosiek et al. 2011). However, in CLL, high Bcl-
2 and Mcl-1 levels have been reported to mediate resistance to chlorambucil, 
fludarabine, and rituximab (Thomas, Pepper et al. 2000; Hussain, Cheney et al. 
2007; Pepper, Lin et al. 2008). Another report finds Mcl-1-dependent leukemias 
are more sensitive to a wide range of chemotherapeutic agents than Bcl-2 
dependent (Brunelle, Ryan et al. 2009).  In addition, we have recently shown that 
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relative expression of Mcl-1 and Bfl-1 to Bcl-2 predicts ABT-737 response in 
hematological cells, including CLL and solid malignancies (Al-Harbi, Hill et al. 
2011). Nevertheless, while numerous studies have focused on the role of Bcl-2 or 
Mcl-1 in CLL, nothing is known about the role of other anti-apoptotic proteins 
and their contribution to clinical outcome in CLL patients. Here, we used RT-
PCR as a highly quantitative and sensitive assay to assess expression of all anti-
apoptotic genes, including Bcl-2, Mcl-1, Bcl-xl, Bcl-w, Bfl-1, Bcl-b and pro-
apoptotic Bim, Puma and Noxa to study their contribution to treatment free 
survival in 76 CLL patients.  Our data indicate that Bcl-xl was the only anti-
apoptotic member to demonstrate a very strong correlation with treatment-free 
survival. Interestingly, Bcl-xl was able to identify patients with high risk in 
ZAP70 negative, CD38 negative groups as well as the p53 unmutated/unknown 
group, which indicates a superior and independent prognostic value. 
 
3.3 Methods 
3.3.1 Purification of primary CLL cells 
     Peripheral blood samples from 76 patients with CLL were obtained with the 
patients’ informed consent according to protocols approved by the Cleveland 
Clinic Institutional Review Board according to the Declaration of Helsinki. All 
primary CLL cells were freshly processed without freezing. Lymphocytes were 
purified by Ficoll-Paque PLUS (GE Healthcare) gradient centrifugation. 
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3.3.2 Flow cytometry 
     It has been previously described in 2.3.3 (Al-Harbi, Hill et al. 2011).  
3.3.3 FISH 
It has been previously described in 2.3.4 
      
3.3.4 RNA isolation and quantitative RT-PCR 
It has been previously described  in 2.3.6 (Al-Harbi, Hill et al. 2011). 
3.3.5 Statistical analysis 
     Cox-proportional hazard models were used to identify significant survival 
dependencies via slope coefficients differing significantly from zero.  To graph 
these dependencies, Kaplan-Meier methods were applied with covariates 
dichotomized at their medians. P values shown in such plots were obtained using 
the log rank test.  Two sample t-tests were used to compare Bcl-xl levels between 
low and high levels of ZAP70, CD38 and p53. All computations were performed 
in R. 
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3.4 Result and discussion 
     Baseline characteristics of the 76 CLL patients studied are summarized in 
(Table 3.1). We have used RT-PCR as a quantitative assay to assess expression all 
anti-apoptotic Bcl-2 family genes: Bcl-2, Mcl-1, Bcl-xl, Bcl-w, Bcl-b and Bfl-1 as 
well as pro-apoptotic members: Bim, Puma and Noxa. We tested the correlation 
of expression level of each member with treatment-free survival (Figure 3.1 and 
3.2). To test the impact of each member on the treatment-free survival, the 
patients were categorized into two subsets, high (above) and low (below) the 
median expression value for each Bcl-2 family member. We also examined the 
combined expression of all anti-apoptotic members, all pro-apoptotic members, 
and the ratio of these, with treatment-free survival.  From all these analyses only 
Bcl-xl expression emerged as significant and correlate with treatment-free 
survival (Figure 3.1A). Interestingly, Bcl-xl expression did not significantly 
correlate with Rai stage (Figure 3.3), CD38, ZAP70, and commonly detected 
chromosomal abnormalities (Table 3.1), indicating that Bcl-xl expression is 
independent of known CLL prognostic markers. We also assessed the correlation 
of common CLL prognostic markers: p53, CD38 and ZAP70 with treatment-free 
survival. Patients with p53 deletion also show very strong correlation with 
treatment-free survival, where ZAP70 and CD38 failed to show any correlation 
with treatment free-survival (Figure 3.4).  
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     Interestingly, we have noticed that some patients in ZAP70 negative, CD38 
negative, normal/unknown p53 categories also experience rapid progression and 
aggressive disease (Figure 3.4). This suggests that some patients in these 
categories are still at high risk, and the current prognostic markers may be limited 
in identifying those patients.  Therefore, we wanted to test the ability of Bcl-xl to 
identify patients with high risk within ZAP70 negative, CD38 negative, and p53 
normal/unknown categories. Surprisingly, Bcl-xl was able to identify patients 
with high risk in the ZAP70 negative and CD38 negative groups as well as 
patients with normal/unknown p53 showing a very strong prognostic value in 
CLL (Figure 3.5). 
      As Bcl-xl provides a comprehensive and powerful prognostic marker in CLL, 
it was not surprising that Bcl-2 and Mcl-1 failed to show significance in 
treatment-free survival since other studies report similar findings (Grever, Lucas 
et al. 2007; Pepper, Lin et al. 2008). There are conflicting reports on the 
significance of ZAP70 and CD38 in predicting the clinical outcome in CLL 
(Grever, Lucas et al. 2007). Lack of method standardization following 
chemotherapy have been associated with the use of these markers (Shanafelt, 
Byrd et al. 2006; Sheikholeslami, Jilani et al. 2006; Van Bockstaele, Verhasselt et 
al. 2009). Despite of these shortcomings, ZAP70, and CD38 are often performed 
as part of the diagnostic evaluation in CLL patients.  An interesting finding of this 
study is that Bcl-xl was able to identify high-risk patients within ZAP70-negative 
and CD38-negative groups. More importantly, the prevalence of p53 deletion or 
mutation has been reported in only a small proportion of CLL patients.  
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Remarkably, Bcl-xl was able to mark patients with high risk in p53 
undeleted/unknown group, which may indicate Bcl-xl as ideal prognostic marker 
in this group. 
     The role of bcl-xl and survival has not been investigated in CLL; however 
recent reports show that Bcl-xl is essential for lymphoma development (Kelly, 
Grabow et al. 2011). In support of our findings, the resistance to a group of 
compounds that repress Mcl-1 expression was correlated with high mRNA 
expression of Bcl-xl, indicating that patients-selection strategy for development of 
any Mcl-1 inhibitor in breast and non-small cells lung carcinoma (NSCLC) 
tumors should be based on patients with low Bcl-xl expression (Wei, Margolin et 
al. 2012). Resistance to 122 standard chemotherapy agents was also correlated 
with high Bcl-xl expression in the NCI 60 cell line panel (Amundson, Myers et al. 
2000) which suggest its unique role in mediating general chemotherapy 
resistance.     
     In summary, in an extensive study that quantify all anti-apoptotic genes by 
using RT-PCR as a simple, highly sensitive, cost effective technique, we propose 
Bcl-xl as an independent prognostic marker that can predict high risk in diverse 
CLL patients. 
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Table 3.1: Baseline characteristic of CLL patients  
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Figure 3.1: Kaplan-Meier curves for correlation of treatment-free survival 
with anti-apoptotic Bcl-2 expression levels. (A) BCL-XL, (B) BCL-2, (C) 
MCL-1, (D) BFL-1, (E) BCL-W, (F) BCL-B. 
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Figure 3.2: Kaplan-Meier curves for correlation of treatment-free survival 
with pro-apoptotic Bcl-2 expression levels. (A) PUMA, (B) NOXA, (C) BIM. 
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Figure 3.3: BCL-XL expression is independent of Rai stage. RNA expression 
of BCL-XL, as determined by quantitative RT-PCR in 0, I, II, III, and IV stages. 
P-values are indicated for comparison between groups. 
.  
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Figure 3.4: Kaplan-Meier curves for correlation of treatment-free survival 
with CLL prognostic markers. (A) 17p deletion, (B) CD38, (C) ZAP70.  
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Figure 3.5: Kaplan-Meier curves for BCL-XL correlation with treatment-
free survival in negative CLL prognostic marker groups. (A) CD38 negative 
group, (B) ZAP70 negative group, (C) 17p negative/unknown group.  
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              CHAPTER IV 
MCL-1 STABILITY DEFINES ABT-737 RESISTANCE IN LEUKEMIC B- 
CELLS 
Mazumder S, Choudhary GS, Al-Harbi S, Almasan A. Cancer Res. 2012 Apr 23.  
 
4.1 Abstract 
     ABT-737 is a small molecule Bcl-2 homology BH3 domain mimetic that binds 
to the Bcl-2 family proteins Bcl-2 and Bcl-xL. Recent clinical trials show that the 
drug is highly effective however, the most effective chemotherapeutics acquired 
resistance is a serious clinical problem. In order to investigate the potential 
mechanism responsible for ABT-737 resistance.  We generated ABT-737 resistant 
(ABT-R) cell lines from initially sensitive Nalm-6 and Reh after chronic exposure 
to ABT-737. Compared with parental cells, cells that have developed acquired 
resistance to ABT-737 showed increased expression of Mcl-1. Mcl-1 was not 
transcriptionally upregulated as there was no difference in constitutive Mcl-1 
mRNA levels in resistant and parental Nalm-6 and Reh cells. Our result indicates 
that increased Mcl-1 levels of ABT-R cells were due to its stabilization at the 
protein. We also show that increased Mcl-1 levels are associated with Bim in 
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ABT-R cells which mediate resistance to ABT-737.  These data therefore reveal 
novel insights into mechanisms of acquired resistance to ABT-737. 
 
4.2 Introduction 
     The interplay between Bcl-2 family members is essential for controlling the 
mitochondrial cell death pathway and thereby the survival of most cells, including 
those of hematopoietic origin. Based on their Bcl-2 homology (BH) domains, the 
Bcl-2 proteins have been grouped in three classes: anti-apoptotic, pro-apoptotic, 
and those with the BH3 domain-only (Chipuk, Moldoveanu et al. 2010; Elkholi, 
Floros et al. 2011). The members of this group regulate mitochondrial outer 
membrane permeabilization (MOMP), monitoring release of cytochrome c and 
activating downstream effector caspases (Chen, Gong et al. 2000). The imbalance 
in expression of these partners has been implicated in development of various 
tumor types and resistance to chemotherapeutic regimens (Chipuk, Moldoveanu et 
al. 2010). This often results from high level expression of anti-apoptotic members, 
such as Bcl-2, Bcl-xL, Mcl-1, Bcl-w, and Bfl-1 that prevent cell death by 
sequestering BH3-only proteins, such as Bim, Puma, and Noxa, and regulate 
activation of the pro-apoptotic proteins Bax and Bak. In most of these cases, up-
regulation and binding of significant amounts of anti-apoptotic proteins to 
activator proteins keeps these cells alive (Letai 2008; Al-Harbi, Hill et al. 2011).  
     ABT-737 is a small molecule inhibitor that is effective against certain Bcl-2 
family members (Oltersdorf, Elmore et al. 2005). It has a strong affinity for Bcl-2, 
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Bcl-xL, and Bcl-w that are bound to Bim  by releasing Bim from anti-apoptotic 
Bcl-2 partners, thereby initiating MOMP (Morales, Kurtoglu et al. 2011). The oral 
derivative of ABT-737, navitoclax (ABT-263) is currently under investigation in 
several clinical trials in lymphoid malignancies, such as chronic lymphocytic 
leukemia (CLL), and tumors, such as small cell lung cancer (Wilson, O'Connor et 
al. 2010; Gandhi, Camidge et al. 2011; Roberts, Seymour et al. 2012). 
Importantly, ABT-737 mediated cell death is Bax/Bak-dependent as Bax/Bak 
double knock-out mouse fibroblasts are resistant to this treatment (van Delft, Wei 
et al. 2006). However, it is expected that even for the most effective 
chemotherapeutics acquired resistance to be a serious clinical problem, hence 
investigate the potential mechanism responsible for acquired resistance is of 
special interest in cancer therapy (Vogler, Dinsdale et al. 2009; Yecies, Carlson et 
al. 2010; Shi, Zhou et al. 2011).  
     ABT-737 has very weak affinity for Mcl-1 (Lee, Czabotar et al. 2007). Various 
studies have shown that sensitivity to ABT-737 is decreased in cells expressing 
elevated levels of Mcl-1 (Konopleva, Contractor et al. 2006; Al-Harbi, Hill et al. 
2011). Moreover, cells initially sensitive to ABT-737 become resistant by up-
regulating Mcl-1 levels (Yecies, Carlson et al. 2010). To investigate the probable 
mechanisms of resistance to ABT-737, resistant cell lines were generated from 
pre-B tumor cells that developed increased levels of Mcl-1 protein. This study 
reveals novel insights into regulation and role of Mcl-1 in response to ABT-737 
resistance. 
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4.3 Materials and Methods 
4.3.1 Cell lines and reagents 
     Human B-cell acute lymphoblastic leukemia (ALL) cell lines Nalm-6 and Reh 
were obtained from ATCC (Manassas, VA). These pre-B cells express CD19 and 
CD127 surface markers with rearranged immunoglobulin heavy chains. Cells 
were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum 
(FBS; Atlanta Biologicals), L-glutamine, Antibiotic-antimycotic (Invitrogen). 
ABT-R cells were cultured in 5% FBS. Cell lines were routinely verified for 
growth rates, morphological characteristics, and response to stimuli using 
Annexin V/Propidium iodide staining. ABT-737 was provided by Abbott 
Laboratories (Abott Park, IL). Actinomycin D, and cycloheximide were from 
Sigma-Aldrich. 
4.3.2 Generation of ABT-737-resistant cell lines 
     Nalm-6 and Reh cells were cultured in increasing concentrations of ABT-737 
administered intermittently, with the drug being washed off to allow cells to 
recover. Gradually, the ABT-737 concentration was increased until cells remained 
viable when ABT-737 concentrations double to that of their IC50 value was 
administered continuously. Cells were treated with verapamil (Sigma-Aldrich) to 
exclude the possibility of acquiring resistance due to increase in expression of 
drug efflux pumps (Safa, Glover et al. 1987). The ABT-R cells were routinely 
monitored for resistance to ABT-737; they were cultured without drug for 72 
hours before performing experiments.  
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4.3.3 Flow cytometry  
     Cell death was measured by phosphatidylserine externalization, by staining 
with fluorescein-conjugated Annexin V (BD Biosciences, San Jose, CA) and 
propidium iodide, and analyzed on a BD FACS Calibur flow cytometer. The raw 
data obtained was analyzed by CellQuest Version 5.2.1 software. The results were 
normalized to survival of control cells that have been treated with DMSO.  
4.3.4 Immunoblotting and immunoprecipitation 
      Protein lysates were prepared with 1% NP-40 lysis buffer (20 mM Tris-HCl, 
pH 7.5; 150 mM Nacl; 1 mM EDTA; 1% NP-40) containing protease inhibitors 
(Roche) and phosphatase inhibitors cocktail 2 and 3 (Sigma). The cells were lysed 
for 30-45 min at 40C°. 50-60 μg of protein was resolved on 10%-12% SDS-
PAGE, transferred to nitrocellulose membrane, and immunoblotting was 
performed with primary antibodies. For immunoprecipitation cells were lysed 
with CHAPS buffer (20 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1 mM EDTA; 2% 
CHAPS, Calbiochem) containing protease and phosphates inhibitors for 1 hour. 
Protein lysates were incubated with primary antibody overnight at 40 C° followed 
by 1 hour incubation of protein A agarose beads (eBioscience, Calbiochem) at 
40C°. Immunoprecipitates were washed 3 times with CHAPS and eluted with 
loading buffer.  
     The co-immunoprecipitated proteins were resolved by SDS-PAGE. Primary 
antibodies used were for Mcl-1, Bim (BD-Biosciences), NOXA (Enzo Life 
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Sciences), Bcl-2, Bcl-xL (Santa Cruz Biotechnology), PUMA (ProSci 
Corporation), USP-9X (Abnova), PARP1 (Cell Signaling), and β-actin (Sigma).  
4.3.5 RNA Isolation and Real-Time Quantitative Polymerase Chain Reaction 
(qRT-PCR) 
      Total RNA was isolated from parental and ABT-R cells after ABT-737 
treatment (500-1000 nM) for 4-24 hours  using the Trizol method (Invitrogen); 2 
µg of RNA was reverse transcribed using the TaqMan reverse transcription kit 
and amplified using the SYBR Green Master Mix (Applied Biosystems, 
N8080234 and 4309155) and examined on a 7500 Real-Time PCR system 
(Applied Biosystems). RNA isolated using primers for Mcl-1 and normalized for 
β-actin as described (Al-Harbi, Hill et al. 2011).  
4.3.6 Confocal immunostaining 
      Cells were fixed with 2.0% paraformaldehyde/PBS for 15 min at room 
temperature, washed 3 times for 10 min each, permeabilized with 0.1% Triton X-
100 in PBS for 5 min, and blocked in 10% fetal bovine serum in PBS for 1 hour. 
The coverslips were then immunostained using Mcl-1 antibody diluted in 
blocking buffer, followed by fluorescently conjugated secondary antibody. DAPI 
and Mito-tracker were added to stain Nucleus and Mitochondria respectfully. 
They were then mounted in Vectashield (Vector Laboratories, H-1000). Images 
were collected using an HCX Plan Apo 63X/1.4N.A. Oil immersion objective 
lens on a Leica TCS-SP2 confocal microscope (Leica Microsystems AG). 
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4.3.7 Statistical Analysis 
     Statistical comparisons between groups were conducted by 2-way ANOVA 
using Prism software. Standard deviation was calculated from experiments 
performed in triplicates and indicated as error bars. All experiments were repeated 
three times independently. 
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4.4 Results 
4.4.1 Acquired resistance of B-cells to ABT-737 after prolonged exposure 
     ABT-737 is a BH3-mimetic that binds only to certain Bcl-2 family proteins, 
such as Bcl-2, Bcl-xL, and Bcl-w, but not Mcl-1. In our previous studies we have 
shown that patients with increased Mcl-1 levels do not respond to ABT-737 and 
thereby become resistant to this drug (Al-Harbi, Hill et al. 2011). Hence, in order 
to investigate the mechanism responsible for resistance, we generated ABT-737-
resistant (ABT-R) cell lines from initially sensitive pre-B Nalm-6 and Reh cells. 
These cell lines were selected for their sensitivity to ABT-737, with IC50 values 
of ~1000 and ~500 nm, respectively. The Nalm-6 ABT-R and Reh ABT-R cells 
generated could tolerate continuous exposure to ABT-737 at a concentration 
double to that of their IC50 value (Fig. 4.1A). In addition, Parental cells were 
sensitive to ABT-737 and within 3 hours they were committed to cell death, as 
indicated by cleavage of poly-(ADP-ribose) polymerase 1(PARP1) (Fig. 4.1B). 
These results indicate that ABT-737 resistant cells are highly resistant to ABT-
737. 
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Figure 4.1. Acquired resistance development in leukemic cells. (A) Parental 
and ABT-737 resistant (ABT-R) Nalm-6 and Reh cells were treated with ABT-
737 for 24 hours. Cell viability is shown as a percentage of Annexin V-FITC/PI-
negative, relative to control cells treated with DMSO, as determined by flow 
cytometric analyses. (B) Parental and ABT-R Nalm-6 cells were treated with 
ABT-737 (1000 nM for 1-3 hours) and expression of PARP1, and β-actin was 
determined by immunobloting. 
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4.4.2 Mcl-1 levels are high in ABT-737 resistant cells 
     Further examination of Bcl-2 family proteins by immunoblotting in parental 
and ABT-R cells indicated increased Mcl-1 levels in ABT-R cells (Fig. 4.2A). 
Bfl-1 levels were below our detection limit. We could also observe decreased Bcl-
2 and increased Bim levels in Reh ABT-R cells, which were comparable to those 
found in Nalm-6 ABT-R cells. Puma and NOXA expression was not markedly 
altered (Fig. 4.2A). Mcl-1 protein levels increased in parental but not in ABT-R 
cells following acute ABT-737 treatment (Fig. 4.2B).  
     Increased Mcl-1 levels were attributed to increased deubiquitination as a result 
of increased levels of the USP9X deubiquitinating enzyme (Schwickart, Huang et 
al. 2010), however, USP9X levels (Fig. 4.2B) and its association with Mcl-1 (data 
not shown) did not change in ABT-R cells.  To validate our immunoblotting data, 
we performed immunostaning experiment to asses expression and localization of 
Mcl-1 in parental and ABT-737 resistant cells. Our data indicate that Mcl-1 
expression is high in ABT-737 resistant cells and predominantly localized in the 
mitochondria (Figure 4.3). Similar results were found for Nalm6R (data not 
shown). Our results show that ABT-737-resistant cells could block apoptosis and 
develop resistance by elevating Mcl-1 levels. 
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Figure 4.2. High Mcl-1 level in ABT-R cells. (A) Whole cell lysates were 
analyzed by immunoblotting for expression of Bcl-2 family proteins and β-actin 
by immunobloting with the indicated primary antibodies. (B) Parental and ABT-R 
Nalm-6 cells were treated with ABT-737 (1000 nM for 1-3 hours) and 
expressions of Bim, USP 9X, PARP, Mcl-1, and β-actin were determined by 
immunobloting. The results are representative of three independent experiments. 
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Figure 4.3 Expression and localization of Mcl-1 in parental and Reh ABT-
737-resistant cells. Confocal co-immunostaining for Reh parental and Reh ABT-
737-resistant cells stained with Mcl-1 (green), Mitochondria (red), and Nucleus 
(blue). 
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4.4.3 ABT-737 resistance is associated with increased Mcl-1 protein stability 
     Previous studies of acquired ABT-737-resistance reported that increased 
expression levels of Mcl-1 in ABT-R cells are a result of increased mRNA levels 
(Yecies, Carlson et al. 2010). However, there was no difference in constitutive 
Mcl-1 mRNA levels in resistant compared to parental Nalm-6 and Reh cells, as 
determined by qRT-PCR (Figure. 4.4 A-B). Similar results were found for Bfl-1 
(data not shown). Most importantly, there was no change in Mcl-1 mRNA levels 
following chronic ABT-737 treatment in Nalm-6 (1000 nM) and Reh (500 nM) 
parental and ABT-R cells. These results indicate that Mcl-1 was not 
transcriptionally upregulated, however do not preclude the possibility of a 
reduced turnover of the Mcl-1 transcript in ABT-737-resistant cells. ABT-R 
Nalm-6 and Reh cells examined up to 2 hours following treatment with 
actinomycin D, a known transcriptional inhibitor, indicated that the half-life of 
Mcl-1 mRNA was not altered (data not shown). In addition, there was no further 
change of Mcl-1 proteins levels in ABT-R cells following 18 hours ABT-737 
exposure (Figure 4.4C). 
     Since the Mcl-1 protein has a very short half-life, Mcl-1 protein stability was 
further evaluated. Immunoblotting following 30-90 min of cycloheximide 
treatment revealed that the half-life of Mcl-1 protein was increased considerably, 
to 60-90 min in ABT-R compared to 15-20 min in parental cells (Fig. 4.5A-C). 
These results indicate that increased Mcl-1 levels of ABT-R cells were due to its 
stabilization at the protein and not at mRNA level. 
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Figure 4.4. Increased Mcl-1 levels in ABT-737-resistant cells are not due to 
regulation of mRNA expression. (A) Mcl-1 mRNA levels were examined by 
quantitative real-time PCR in parental and ABT-R Nalm-6 and Reh cells 
following ABT-737 treatment (1000 nM for Nalm-6 ABT-R and 500 nM for Reh 
ABT-R) for 4, 8 and 24 hours. (B) Analyses of Mcl-1 mRNA basal levels were 
performed in parental and ABT-737-resistant Nalm-6 and Reh cells by 
quantitative real-time PCR.  (C) ABT-R cells were treated with ABT-737 (1000 
nM for Nalm-6 ABT-R and 500 nM for Reh ABT-R) for 18 hours and 
immunoblotted with Mcl-1 and β-actin primary antibodies. 
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Figure 4.5. Mcl-1 levels are regulated by protein stabilization. (A) Mcl-1 
protein stability was determined following 10 µg/ml cycloheximide (CHX) 
treatment in Nalm-6 and Nalm-6 ABT-R cells. (B) Nalm-6 and Nalm-6 ABT-R 
cells were pretreated with ABT-737 (500 nM) for 3 hours prior to exposure to 
CHX to determine Mcl-1 protein stability. (C) Mcl-1 protein half-life was 
determined in Reh and Reh ABT-R cells following CHX treatment.  
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4.4.4 Increased Mcl-1 levels sequester Bim following its displacement from 
Bcl-2 and Bcl-xl complexes in ABT-R cells 
     It has been reported that increased Mcl-1 levels in ABT-R cells associate with 
Bim after its competitive dissociation from Bcl-2/Bcl-xl complexes by ABT-737. 
Importantly, displacement of Bim from Bcl-2/Bcl-xl complexes by ABT-737 in 
sensitive cells was shown to be a critical event for committing cells to death 
(Yecies, Carlson et al. 2010). We investigated the interaction of Bim with Mcl-1, 
Bcl-2, and Bcl-xl in parental and ABT-R Nalm-6 cells. There was less association 
of Bim with Bcl-2/Bcl-xl in ABT-R compared to parental Nalm-6 cells, which 
was in contrast to binding of Bim to Mcl-1 (Figure 4.6A). Indeed, our co-
immunoprecipitation analyses indicated that association of Mcl-1 with Bim in 
ABT-R cells was more pronounced compared to those in parental cells. These 
results were confirmed by reciprocal immunoprecipitation-immunoblot analyses 
with Mcl-1 and Bim, respectively (Figure 4.6B). On other hand, there was more 
Bim present that was not bound to Mcl-1 in parental cells, instead was found in 
the supernatant following immunodepletion of Mcl-1 (Figure 4.6B). Taken 
altogether, these data suggest that Bim was dissociated from Bcl-2/Bcl-xl 
complexes by competitive displacement by ABT-737. Moreover, this displaced 
Bim was bound to Mcl-1 in resistant but not in parental cells, even when ABT-
737 was absent.  Similar observations were made in Reh ABT-R cells (data not 
shown). 
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Figure 4.6. Increased Mcl-1 levels are associated with Bim in ABT-R cells. 
(A) Bim was immunoprecipitated and immunoblot analyses were performed for 
Mcl-1, Bcl-2, Bcl-xl, and Bim. (B) Reciprocal immunoprecipitation analysis was 
performed for Mcl-1 followed by immunoblotting for Bim to determine Mcl-1 
bound and free Bim. Bim was immunoprecipitates from cells treated with ABT-
737 (1000 nM) for 3 hours and immunoblotted for Mcl-1 and Bim to determine 
the proportion of Mcl-1-bound and Mcl-1-free Bim. 
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4.5 Discussion 
     Acquired resistance is a concern for chemotherapeutic treatments used for 
leukemia, and other malignancies. Although there have been basic advances in 
understanding the mechanisms for this resistance, few efforts have been made to 
study the contribution of post-translational regulation of proteins that leads to 
such resistance. The focus of our current studies was to understand the 
mechanism responsible for acquired ABT-737 resistance in leukemic cells. 
Nuclear magnetic resonance (NMR) studies have shown that ABT-737 binds to 
Bcl-2, Bcl-xl, and Bcl-w at sub-nM concentrations, but not to Mcl-1. Hence, Mcl-
1 levels can determine ABT-737 sensitivity (Yecies, Carlson et al. 2010). 
Moreover, increased levels of these proteins can be a frequent cause of resistance. 
Various drugs, such as flavopiridol, R-roscovitine (Seliciclib), and PHA 767491 
that downregulate Mcl-1 at mRNA level are being tested for sensitizing such 
tumor cells (Raje, Kumar et al. 2005; Yecies, Carlson et al. 2010).  
     Recently, sorafenib (BAY43-9006;Nexavar) was shown to induce apoptosis by 
downregulation of Mcl-1 at translational rather than post-translational level 
(Huber, Oelsner et al. 2011). This study has examined the molecular mechanism 
for acute versus chronic response to ABT-737 in leukemic cells. Recent studies 
and our previous report indicate that increased levels of Mcl-1 accumulate in 
ABT-R cells, with Mcl-1 being bound to Bim significantly more in resistant 
compared to parental cells (Yecies, Carlson et al. 2010; Al-Harbi, Hill et al. 
2011). As in our leukemic model of ABT-737 resistance, Mcl-1 was not 
upregulated at transcriptional level, led us to explore its protein stability. Previous 
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studies have shown that post-translational modifications, such as phosphorylation 
of Mcl-1 at specific residues are important for it’s binding to BH3-only proteins 
and its stability (Kobayashi, Lee et al. 2007; Liao, Zhao et al. 2011). Mcl-1 is a 
short-lived protein and it is a target of E3 ubiquitin ligases that mediate its 
proteasomal-mediated degradation. Mcl-1 is inaccessible to E3-ubiquitin ligases, 
FBW7 and β-Trcp when it is bound to BH3-only proteins, such as Bim, as more 
association of Bim with Mcl-1 prevents their access to Mcl-1. As there is 
competitive binding between these E3-ubiquitin ligases and BH3-only proteins 
because they share the same C-terminal-binding region of Mcl-1 (Hogarty 2010), 
most likely this could contribute towards Mcl-1 stability, as more Bim is 
associated with Mcl-1 in ABT-R cells. These findings provide insights into the 
molecular mechanism of ABT-737 resistance. 
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CHAPTER V 
FUTURE DIRECTIONS 
 
5.1 Introduction 
     Apoptosis is often blocked in cancer, which limits the response to conventional 
therapy. Resistance of tumor cells to conventional chemotherapy may be caused 
by a defect in the apoptosis machinery. It is clear that high levels of anti-apoptotic 
proteins have been reported in many human malignancies and generally correlate 
with aggressive tumors and chemotherapeutic resistance. However, it is not clear 
how to apply the expression of anti-apoptotic Bcl-2 genes in a rational way to 
predict the maximum response to current chemotherapy regimens in cancer 
patients.  
     We have developed a marker that can be used to predict responses in leukemia, 
including CLL as well as small cell lung carcinomas cells. We have also shown 
that combining ABT-737 with agents that target high Mcl-1 levels, such as 
flavopiridol, can improve the clinical response in highly ABT-737-resistant cells. 
However, data from the flavopiridol clinical trials indicate that the drug is not 
quite safe, as there is a substantial risk for tumor lysis syndrome (TLS) in the 
treated relapsed CLL patients (Blum, Ruppert et al. 2011). Therefore, we wanted 
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to test whether disrupting the proliferative signal that mediates the growth and 
survival of CLL cells, along with ABT-737, will lead to increased response rates 
in CLL patients.   
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5.2 Effect of ABT-737 in combination with CAL-101 on ABT-737-resistant 
cells. 
     CAL-101 is a novel small molecule inhibitor of the delta isoform of 
phosphatidylinositol 3-kinase. CAL-101 targets the B-cell receptor that is reported 
to promote CLL cell growth and survival, which can block the interaction 
between the tumor microenvironment and CLL cells (Herman, Lapalombella et al. 
2011; Hoellenriegel, Meadows et al. 2011). The drug is available for oral use, is 
well tolerated, and shows impressive clinical effects in phase I trials of refractory 
hematologic malignancies including CLL (Lin 2010).  
     To test whether combining ABT-737 and CAL-101 would improve the clinical 
response in CLL, we have treated several primary CLL cells with ABT-737 alone 
or in combination with CAL-101. Our data indicate that the combination 
treatment shows a synergistic effect more than a single treatment of ABT-737 or 
CAL-101. However, we need to collect more ABT-737-resistant cells to have an 
adequate number of CLL samples. We also want to investigate how cell death is  
mediated by the combination treatment and whether the response is Mcl-1 
dependent. 
 
5.3 Anti-apoptotic Bcl-2 profiling as a clinical tool in follow-up patients. 
     We have used RT-PCR as a highly quantitative assay to study the expression 
of the anti-apoptotic Bcl-2 family genes. Unlike other techniques that have been 
used in the clinic, our assay can quantify all known anti-apoptotic Bcl-2 or any 
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other gene transcripts. It is also highly sensitive, simple, cost-effective and most 
importantly, requires only small number of cells. As we have applied this assay to 
quantify the expression ratio of Mcl-1, Bfl-1, and Bcl-2 to predict response to 
ABT-737, we wanted to take this assay to the next level by assessing the 
expression level of anti-apoptotic genes in follow-up CLL patients. We have 
generated a large cDNA library of CLL patients, with complete Bcl-2 family 
expression profiling. The patients all come to the clinic for follow-up visit. 
Therefore, we wanted to compare the anti-apoptotic Bcl-2 profiling between the 
first and the second visit. We also wanted to test whether the difference can be 
correlated to any clinical outcome such as disease progression or clinical 
response. This assay can quantify the modulation in the anti-apoptotic Bcl-2 
expression following chemotherapy treatment. Thus, it would allow us to identify 
whether CLL cells are Bcl-2 dependent or Mcl-1 dependent, which will provide a 
rational way to choose the ideal chemotherapy treatment in order to maximize the 
clinical response.  
 
     We have collected 17 follow-up cases. The period between the first and second 
sample collection ranges between four to 12 months. We compared the expression 
levels of Bcl-2, Mcl-1, and Bfl-1 in these samples. We did not detect any 
significant difference in the Mcl-1 expression levels between the first and the 
second samples. There was a significant increase in Bcl-2 and Bfl-1 expressions 
in 7 out of 17 samples (Figure 5.1), and 3 out 7 show some tumor progression 
such as lymph node enlargement. These  preliminary data were not significant, as 
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more CLL samples as well as longer time to monitor are needed in order to have 
significant data on those patients. It is also important to expand the anti-apoptotic 
profiling to include other anti-apoptotic Bcl-2 family members, such as Bcl-xl, in 
the study.   
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Figure 5.2 High expressions of Bcl-2 and Bfl-1 in follow-up CLL patients. 
Comparison in RNA expression of anti-apoptotic Bcl-2 family members (A) Bcl-
2, and (B) Bfl-1 as determined by quantitative RT-PCR between 1
st
 and 2
nd
 CLL 
samples. 
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5.4 To investigate whether high Bcl-xl expression is mediated by somatic 
genetic alterations in CLL patients 
     We have shown that CLL patients with a high Bcl-xl level show significantly 
short treatment-free survival. It is well known that cancer progression is driven 
mainly through somatic genetic alterations including, gene amplification and 
translocations (Beroukhim, Mermel et al. 2010). It is highly valuable to identify 
any alteration within a key gene that has a critical role in oncogenesis, such as 
Bcl-xl. A recent report shows that Bcl-xl mediates general resistance to many 
chemotherapy regimens, however, no data to show whether Bcl-xl upregulation is 
due to genetic alterations in CLL patients. The ideal approach to address this issue 
is to sequence Bcl-xl gene. However, this would be costly and time consuming.  
     I hypothesize that high Bcl-xl expression is mediated by gene amplification or 
chromosomal translocation that can place the bcl-xl gene under the control of a 
highly expressed gene. To test my hypothesis, I will use newly custom-designed 
Bcl-xl probes to test whether high Bcl-xl is mediated by gene amplification or 
chromosomal translocation in a few CLL patients that are known to have high 
Bcl-xl using FISH technique.  
 
     The second hypothesize is  that Bcl-xl could be upregulated due to deletion of 
any microRNA that negatively regulates the Bcl-xl transcript. To test this 
hypothesis, I will conduct miroRNA profiling in a small number of our cDNA 
samples to identify a miroRNA candidate that can be involved in Bcl-xl 
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regulation. These hypotheses do not exclude the possibility that high levels of 
Bcl-xl can be due to genetic alterations that constitutively activate its upstream 
signaling, such as NF-kb. 
 
5.5 Conclusion 
     Apoptosis is often impaired in cancer, which can significantly limit the 
response to conventional therapy. Since many anti-cancer regimens kill tumor 
cells through the mitochondrial pathway, resistance of tumor cells to radiation or 
chemotherapy can be due to high levels of anti-apoptotic proteins. However, 
applying anti-apoptotic profiling as a diagnostic tool to predict clinical response  
is not yet feasible. 
     In an effort to accomplish this goal, we have shown that our anti-apoptotic 
index can identify which CLL patients are most likely to respond to ABT-737, 
which cannot be predicted using traditional prognostic markers. We have also 
shown that Bcl-xl can be used as a prognostic marker to identify CLL patients that 
can be at high risk. This study provides insight into the useful application of anti-
apoptotic profiling as a clinical tool, and can be a step toward applying 
personalized treatment, which may maximize the clinical response in cancer 
patients. 
 
 
 119 
BIBLIOGRAPHY 
Adams, J. M. and S. Cory (2007). "The Bcl-2 apoptotic switch in cancer development 
and therapy." Oncogene 26(9): 1324-1337. 
Aerbajinai, W., M. Giattina, et al. (2003). "The proapoptotic factor Nix is coexpressed 
with Bcl-xL during terminal erythroid differentiation." Blood 102(2): 712-717. 
Al-Harbi, S., B. T. Hill, et al. (2011). "An antiapoptotic BCL-2 family expression index 
predicts the response of chronic lymphocytic leukemia to ABT-737." Blood 
118(13): 3579-3590. 
Almasan, A. and A. Ashkenazi (2003). "Apo2L/TRAIL: apoptosis signaling, biology, 
and potential for cancer therapy." Cytokine Growth Factor Rev 14(3-4): 337-348. 
Amundson, S. A., T. G. Myers, et al. (2000). "An informatics approach identifying 
markers of chemosensitivity in human cancer cell lines." Cancer Res 60(21): 
6101-6110. 
Ashkenazi, A. (2002). "Targeting death and decoy receptors of the tumour-necrosis factor 
superfamily." Nat Rev Cancer 2(6): 420-430. 
Autret, A. and S. J. Martin (2009). "Emerging role for members of the Bcl-2 family in 
mitochondrial morphogenesis." Mol Cell 36(3): 355-363. 
Bannerji, R., S. Kitada, et al. (2003). "Apoptotic-regulatory and complement-protecting 
protein expression in chronic lymphocytic leukemia: relationship to in vivo 
rituximab resistance." J Clin Oncol 21(8): 1466-1471. 
Bazargan, A., C. S. Tam, et al. (2012). "Predicting survival in chronic lymphocytic 
leukemia." Expert Rev Anticancer Ther 12(3): 393-403. 
 120 
Beroukhim, R., C. H. Mermel, et al. (2010). "The landscape of somatic copy-number 
alteration across human cancers." Nature 463(7283): 899-905. 
Beverly, L. J., W. W. Lockwood, et al. (2012). "Ubiquitination, localization, and stability 
of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by 
Ubiquilin1." Proc Natl Acad Sci U S A 109(3): E119-126. 
Bharatham, N., S. W. Chi, et al. (2011). "Molecular basis of Bcl-X(L)-p53 interaction: 
insights from molecular dynamics simulations." PLoS One 6(10): e26014. 
Blum, K. A., A. S. Ruppert, et al. (2011). "Risk factors for tumor lysis syndrome in 
patients with chronic lymphocytic leukemia treated with the cyclin-dependent 
kinase inhibitor, flavopiridol." Leukemia 25(9): 1444-1451. 
Bottcher, S., M. Ritgen, et al. (2012). "Minimal Residual Disease Quantification Is an 
Independent Predictor of Progression-Free and Overall Survival in Chronic 
Lymphocytic Leukemia: A Multivariate Analysis From the Randomized 
GCLLSG CLL8 Trial." J Clin Oncol 30(9): 980-988. 
Bouillet, P., D. Metcalf, et al. (1999). "Proapoptotic Bcl-2 relative Bim required for 
certain apoptotic responses, leukocyte homeostasis, and to preclude 
autoimmunity." Science 286(5445): 1735-1738. 
Bouillet, P. and A. Strasser (2002). "BH3-only proteins - evolutionarily conserved 
proapoptotic Bcl-2 family members essential for initiating programmed cell 
death." J Cell Sci 115(Pt 8): 1567-1574. 
Brunelle, J. K., J. Ryan, et al. (2009). "MCL-1-dependent leukemia cells are more 
sensitive to chemotherapy than BCL-2-dependent counterparts." J Cell Biol 
187(3): 429-442. 
 121 
Calin, G. A., M. Ferracin, et al. (2005). "A MicroRNA signature associated with 
prognosis and progression in chronic lymphocytic leukemia." N Engl J Med 
353(17): 1793-1801. 
Certo, M., V. Del Gaizo Moore, et al. (2006). "Mitochondria primed by death signals 
determine cellular addiction to antiapoptotic BCL-2 family members." Cancer 
Cell 9(5): 351-365. 
Chen, C. J., H. Kono, et al. (2007). "Identification of a key pathway required for the 
sterile inflammatory response triggered by dying cells." Nat Med 13(7): 851-856. 
Chen, Q., B. Gong, et al. (2000). "Distinct stages of cytochrome c release from 
mitochondria: evidence for a feedback amplification loop linking caspase 
activation to mitochondrial dysfunction in genotoxic stress induced apoptosis." 
Cell Death Differ 7(2): 227-233. 
Chen, Q., B. Gong, et al. (2001). "Apo2L/TRAIL and Bcl-2-related proteins regulate type 
I interferon-induced apoptosis in multiple myeloma." Blood 98(7): 2183-2192. 
Chen, S., Y. Dai, et al. (2007). "Mcl-1 down-regulation potentiates ABT-737 lethality by 
cooperatively inducing Bak activation and Bax translocation." Cancer Res 67(2): 
782-791. 
Cheng, E. H., D. G. Kirsch, et al. (1997). "Conversion of Bcl-2 to a Bax-like death 
effector by caspases." Science 278(5345): 1966-1968. 
Cheng, E. H., M. C. Wei, et al. (2001). "BCL-2, BCL-X(L) sequester BH3 domain-only 
molecules preventing BAX- and BAK-mediated mitochondrial apoptosis." Mol 
Cell 8(3): 705-711. 
 122 
Chiorazzi, N., K. R. Rai, et al. (2005). "Chronic lymphocytic leukemia." N Engl J Med 
352(8): 804-815. 
Chipuk, J. E., L. Bouchier-Hayes, et al. (2005). "PUMA couples the nuclear and 
cytoplasmic proapoptotic function of p53." Science 309(5741): 1732-1735. 
Chipuk, J. E., T. Moldoveanu, et al. (2010). "The BCL-2 family reunion." Mol Cell 
37(3): 299-310. 
Cimmino, A., G. A. Calin, et al. (2005). "miR-15 and miR-16 induce apoptosis by 
targeting BCL2." Proc Natl Acad Sci U S A 102(39): 13944-13949. 
Cory, S. and J. M. Adams (2002). "The Bcl2 family: regulators of the cellular life-or-
death switch." Nat Rev Cancer 2(9): 647-656. 
Cory, S., D. C. Huang, et al. (2003). "The Bcl-2 family: roles in cell survival and 
oncogenesis." Oncogene 22(53): 8590-8607. 
Crosby, M. E., J. Jacobberger, et al. (2007). "E2F4 regulates a stable G2 arrest response 
to genotoxic stress in prostate carcinoma." Oncogene 26(13): 1897-1909. 
Damle, R. N., T. Wasil, et al. (1999). "Ig V gene mutation status and CD38 expression as 
novel prognostic indicators in chronic lymphocytic leukemia." Blood 94(6): 1840-
1847. 
Datta, S. R., H. Dudek, et al. (1997). "Akt phosphorylation of BAD couples survival 
signals to the cell-intrinsic death machinery." Cell 91(2): 231-241. 
Del Gaizo Moore, V., J. R. Brown, et al. (2007). "Chronic lymphocytic leukemia requires 
BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist 
ABT-737." J Clin Invest 117(1): 112-121. 
 123 
Del Poeta, G., L. Maurillo, et al. (2001). "Clinical significance of CD38 expression in 
chronic lymphocytic leukemia." Blood 98(9): 2633-2639. 
Deng, J., N. Carlson, et al. (2007). "BH3 profiling identifies three distinct classes of 
apoptotic blocks to predict response to ABT-737 and conventional 
chemotherapeutic agents." Cancer Cell 12(2): 171-185. 
Derenne, S., B. Monia, et al. (2002). "Antisense strategy shows that Mcl-1 rather than 
Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells." Blood 
100(1): 194-199. 
Dijkers, P. F., R. H. Medema, et al. (2000). "Expression of the pro-apoptotic Bcl-2 family 
member Bim is regulated by the forkhead transcription factor FKHR-L1." Curr 
Biol 10(19): 1201-1204. 
Dohner, H., S. Stilgenbauer, et al. (2000). "Genomic aberrations and survival in chronic 
lymphocytic leukemia." N Engl J Med 343(26): 1910-1916. 
Domina, A. M., J. A. Vrana, et al. (2004). "MCL1 is phosphorylated in the PEST region 
and stabilized upon ERK activation in viable cells, and at additional sites with 
cytotoxic okadaic acid or taxol." Oncogene 23(31): 5301-5315. 
Elkholi, R., K. V. Floros, et al. (2011). "The Role of BH3-Only Proteins in Tumor Cell 
Development, Signaling, and Treatment." Genes Cancer 2(5): 523-537. 
Fan, G., M. J. Simmons, et al. (2010). "Defective ubiquitin-mediated degradation of 
antiapoptotic Bfl-1 predisposes to lymphoma." Blood 115(17): 3559-3569. 
Gandhi, L., D. R. Camidge, et al. (2011). "Phase I study of Navitoclax (ABT-263), a 
novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other 
solid tumors." J Clin Oncol 29(7): 909-916. 
 124 
Gardner, C. R. (2004). "Anticancer drug development based on modulation of the Bcl-2 
family core apoptosis mechanism." Expert Rev Anticancer Ther 4(6): 1157-1177. 
Glaser, S. P., E. F. Lee, et al. (2012). "Anti-apoptotic Mcl-1 is essential for the 
development and sustained growth of acute myeloid leukemia." Genes Dev 26(2): 
120-125. 
Gonzalez, D., P. Martinez, et al. (2011). "Mutational status of the TP53 gene as a 
predictor of response and survival in patients with chronic lymphocytic leukemia: 
results from the LRF CLL4 trial." J Clin Oncol 29(16): 2223-2229. 
Gores, G. J. and S. H. Kaufmann (2012). "Selectively targeting Mcl-1 for the treatment of 
acute myelogenous leukemia and solid tumors." Genes Dev 26(4): 305-311. 
Gottardi, D., A. Alfarano, et al. (1996). "In leukaemic CD5+ B cells the expression of 
BCL-2 gene family is shifted toward protection from apoptosis." Br J Haematol 
94(4): 612-618. 
Grad, J. M., X. R. Zeng, et al. (2000). "Regulation of Bcl-xL: a little bit of this and a little 
bit of STAT." Curr Opin Oncol 12(6): 543-549. 
Grever, M. R., D. M. Lucas, et al. (2007). "Comprehensive assessment of genetic and 
molecular features predicting outcome in patients with chronic lymphocytic 
leukemia: results from the US Intergroup Phase III Trial E2997." J Clin Oncol 
25(7): 799-804. 
Grumont, R. J., I. J. Rourke, et al. (1999). "Rel-dependent induction of A1 transcription is 
required to protect B cells from antigen receptor ligation-induced apoptosis." 
Genes Dev 13(4): 400-411. 
 125 
Hakem, R., A. Hakem, et al. (1998). "Differential requirement for caspase 9 in apoptotic 
pathways in vivo." Cell 94(3): 339-352. 
Hallek, M., K. Fischer, et al. (2010). "Addition of rituximab to fludarabine and 
cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, 
open-label, phase 3 trial." Lancet 376(9747): 1164-1174. 
Hamblin, T. J., Z. Davis, et al. (1999). "Unmutated Ig V(H) genes are associated with a 
more aggressive form of chronic lymphocytic leukemia." Blood 94(6): 1848-
1854. 
Hanada, M., D. Delia, et al. (1993). "bcl-2 gene hypomethylation and high-level 
expression in B-cell chronic lymphocytic leukemia." Blood 82(6): 1820-1828. 
Hanahan, D. and R. A. Weinberg (2011). "Hallmarks of cancer: the next generation." Cell 
144(5): 646-674. 
Hann, C. L., V. C. Daniel, et al. (2008). "Therapeutic efficacy of ABT-737, a selective 
inhibitor of BCL-2, in small cell lung cancer." Cancer Res 68(7): 2321-2328. 
Herman, S. E., R. Lapalombella, et al. (2011). "The role of phosphatidylinositol 3-kinase-
delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic 
leukemia." Blood 117(16): 4323-4327. 
High, L. M., B. Szymanska, et al. (2010). "The Bcl-2 homology domain 3 mimetic ABT-
737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in 
synergistic in vitro and in vivo interactions with established drugs." Mol 
Pharmacol 77(3): 483-494. 
 126 
Hoellenriegel, J., S. A. Meadows, et al. (2011). "The phosphoinositide 3'-kinase delta 
inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in 
chronic lymphocytic leukemia." Blood 118(13): 3603-3612. 
Hogarty, M. D. (2010). "Mcl1 becomes ubiquitin-ous: new opportunities to antagonize a 
pro-survival protein." Cell Res 20(4): 391-393. 
Huang, D. C. and A. Strasser (2000). "BH3-Only proteins-essential initiators of apoptotic 
cell death." Cell 103(6): 839-842. 
Huber, S., M. Oelsner, et al. (2011). "Sorafenib induces cell death in chronic lymphocytic 
leukemia by translational downregulation of Mcl-1." Leukemia 25(5): 838-847. 
Hussain, S. R., C. M. Cheney, et al. (2007). "Mcl-1 is a relevant therapeutic target in 
acute and chronic lymphoid malignancies: down-regulation enhances rituximab-
mediated apoptosis and complement-dependent cytotoxicity." Clin Cancer Res 
13(7): 2144-2150. 
Inuzuka, H., S. Shaik, et al. (2011). "SCF(FBW7) regulates cellular apoptosis by 
targeting MCL1 for ubiquitylation and destruction." Nature 471(7336): 104-109. 
Jiang, C. C., K. Lucas, et al. (2008). "Up-regulation of Mcl-1 is critical for survival of 
human melanoma cells upon endoplasmic reticulum stress." Cancer Res 68(16): 
6708-6717. 
Kelly, P. N., S. Grabow, et al. (2011). "Endogenous Bcl-xL is essential for Myc-driven 
lymphomagenesis in mice." Blood 118(24): 6380-6386. 
Kerr, J. F., A. H. Wyllie, et al. (1972). "Apoptosis: a basic biological phenomenon with 
wide-ranging implications in tissue kinetics." Br J Cancer 26(4): 239-257. 
 127 
Kitada, S., J. Andersen, et al. (1998). "Expression of apoptosis-regulating proteins in 
chronic lymphocytic leukemia: correlations with In vitro and In vivo 
chemoresponses." Blood 91(9): 3379-3389. 
Knudson, C. M., K. S. Tung, et al. (1995). "Bax-deficient mice with lymphoid 
hyperplasia and male germ cell death." Science 270(5233): 96-99. 
Kobayashi, S., S. H. Lee, et al. (2007). "Serine 64 phosphorylation enhances the 
antiapoptotic function of Mcl-1." J Biol Chem 282(25): 18407-18417. 
Konopleva, M., R. Contractor, et al. (2006). "Mechanisms of apoptosis sensitivity and 
resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia." Cancer Cell 
10(5): 375-388. 
Kvansakul, M., H. Yang, et al. (2008). "Vaccinia virus anti-apoptotic F1L is a novel Bcl-
2-like domain-swapped dimer that binds a highly selective subset of BH3-
containing death ligands." Cell Death Differ 15(10): 1564-1571. 
Lee, E. F., P. E. Czabotar, et al. (2007). "Crystal structure of ABT-737 complexed with 
Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family." Cell 
Death Differ 14(9): 1711-1713. 
Lee, J. S., D. O. Dixon, et al. (1987). "Prognosis of chronic lymphocytic leukemia: a 
multivariate regression analysis of 325 untreated patients." Blood 69(3): 929-936. 
Lessene, G., P. E. Czabotar, et al. (2008). "BCL-2 family antagonists for cancer therapy." 
Nat Rev Drug Discov 7(12): 989-1000. 
Letai, A., M. C. Bassik, et al. (2002). "Distinct BH3 domains either sensitize or activate 
mitochondrial apoptosis, serving as prototype cancer therapeutics." Cancer Cell 
2(3): 183-192. 
 128 
Letai, A. G. (2008). "Diagnosing and exploiting cancer's addiction to blocks in 
apoptosis." Nat Rev Cancer 8(2): 121-132. 
Li, H., H. Zhu, et al. (1998). "Cleavage of BID by caspase 8 mediates the mitochondrial 
damage in the Fas pathway of apoptosis." Cell 94(4): 491-501. 
Li, J., J. Viallet, et al. (2008). "A small molecule pan-Bcl-2 family inhibitor, GX15-070, 
induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung 
cancer cells." Cancer Chemother Pharmacol 61(3): 525-534. 
Li, P., D. Nijhawan, et al. (1997). "Cytochrome c and dATP-dependent formation of 
Apaf-1/caspase-9 complex initiates an apoptotic protease cascade." Cell 91(4): 
479-489. 
Liao, M., J. Zhao, et al. (2011). "Role of bile salt in regulating Mcl-1 phosphorylation 
and chemoresistance in hepatocellular carcinoma cells." Mol Cancer 10: 44. 
Lin, B., S. K. Kolluri, et al. (2004). "Conversion of Bcl-2 from protector to killer by 
interaction with nuclear orphan receptor Nur77/TR3." Cell 116(4): 527-540. 
Lin, T. S. (2010). "New agents in chronic lymphocytic leukemia." Curr Hematol Malig 
Rep 5(1): 29-34. 
Lin, T. S., A. S. Ruppert, et al. (2009). "Phase II study of flavopiridol in relapsed chronic 
lymphocytic leukemia demonstrating high response rates in genetically high-risk 
disease." J Clin Oncol 27(35): 6012-6018. 
Lindsten, T., A. J. Ross, et al. (2000). "The combined functions of proapoptotic Bcl-2 
family members bak and bax are essential for normal development of multiple 
tissues." Mol Cell 6(6): 1389-1399. 
 129 
Luciano, F., A. Jacquel, et al. (2003). "Phosphorylation of Bim-EL by Erk1/2 on serine 
69 promotes its degradation via the proteasome pathway and regulates its 
proapoptotic function." Oncogene 22(43): 6785-6793. 
Luo, X., I. Budihardjo, et al. (1998). "Bid, a Bcl2 interacting protein, mediates 
cytochrome c release from mitochondria in response to activation of cell surface 
death receptors." Cell 94(4): 481-490. 
Marchenko, N. D., A. Zaika, et al. (2000). "Death signal-induced localization of p53 
protein to mitochondria. A potential role in apoptotic signaling." J Biol Chem 
275(21): 16202-16212. 
Mason, K. D., S. L. Khaw, et al. (2009). "The BH3 mimetic compound, ABT-737, 
synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic 
leukemia." Leukemia 23(11): 2034-2041. 
Maurer, U., C. Charvet, et al. (2006). "Glycogen synthase kinase-3 regulates 
mitochondrial outer membrane permeabilization and apoptosis by destabilization 
of MCL-1." Mol Cell 21(6): 749-760. 
Michels, J., J. W. O'Neill, et al. (2004). "Mcl-1 is required for Akata6 B-lymphoma cell 
survival and is converted to a cell death molecule by efficient caspase-mediated 
cleavage." Oncogene 23(28): 4818-4827. 
Miyashita, T. and J. C. Reed (1995). "Tumor suppressor p53 is a direct transcriptional 
activator of the human bax gene." Cell 80(2): 293-299. 
Monni, O., H. Joensuu, et al. (1997). "BCL2 overexpression associated with 
chromosomal amplification in diffuse large B-cell lymphoma." Blood 90(3): 
1168-1174. 
 130 
Morales, A. A., M. Kurtoglu, et al. (2011). "Distribution of Bim determines Mcl-1 
dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma 
cells." Blood 118(5): 1329-1339. 
Motoyama, N., F. Wang, et al. (1995). "Massive cell death of immature hematopoietic 
cells and neurons in Bcl-x-deficient mice." Science 267(5203): 1506-1510. 
Mott, J. L., S. Kobayashi, et al. (2007). "mir-29 regulates Mcl-1 protein expression and 
apoptosis." Oncogene 26(42): 6133-6140. 
Muchmore, S. W., M. Sattler, et al. (1996). "X-ray and NMR structure of human Bcl-xL, 
an inhibitor of programmed cell death." Nature 381(6580): 335-341. 
Nakano, K. and K. H. Vousden (2001). "PUMA, a novel proapoptotic gene, is induced by 
p53." Mol Cell 7(3): 683-694. 
Ni Chonghaile, T., K. A. Sarosiek, et al. (2011). "Pretreatment mitochondrial priming 
correlates with clinical response to cytotoxic chemotherapy." Science 334(6059): 
1129-1133. 
Nordigarden, A., M. Kraft, et al. (2009). "BH3-only protein Bim more critical than Puma 
in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and 
transduced hematopoietic progenitors carrying oncogenic FLT3." Blood 113(10): 
2302-2311. 
Nuckel, H., U. H. Frey, et al. (2007). "Association of a novel regulatory polymorphism (-
938C>A) in the BCL2 gene promoter with disease progression and survival in 
chronic lymphocytic leukemia." Blood 109(1): 290-297. 
 131 
Oberstein, A., P. D. Jeffrey, et al. (2007). "Crystal structure of the Bcl-XL-Beclin 1 
peptide complex: Beclin 1 is a novel BH3-only protein." J Biol Chem 282(17): 
13123-13132. 
Oda, E., R. Ohki, et al. (2000). "Noxa, a BH3-only member of the Bcl-2 family and 
candidate mediator of p53-induced apoptosis." Science 288(5468): 1053-1058. 
Olejniczak, E. T., C. Van Sant, et al. (2007). "Integrative genomic analysis of small-cell 
lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers 
novel chromosomal gains." Mol Cancer Res 5(4): 331-339. 
Olsson, A., M. Norberg, et al. (2007). "Upregulation of bfl-1 is a potential mechanism of 
chemoresistance in B-cell chronic lymphocytic leukaemia." Br J Cancer 97(6): 
769-777. 
Oltersdorf, T., S. W. Elmore, et al. (2005). "An inhibitor of Bcl-2 family proteins induces 
regression of solid tumours." Nature 435(7042): 677-681. 
Orchard, J. A., R. E. Ibbotson, et al. (2004). "ZAP-70 expression and prognosis in 
chronic lymphocytic leukaemia." Lancet 363(9403): 105-111. 
Paoluzzi, L., M. Gonen, et al. (2008). "Targeting Bcl-2 family members with the BH3 
mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic 
agents in in vitro and in vivo models of B-cell lymphoma." Blood 111(11): 5350-
5358. 
Pepper, C., T. Hoy, et al. (1998). "Elevated Bcl-2/Bax are a consistent feature of 
apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated 
with in vivo chemoresistance." Leuk Lymphoma 28(3-4): 355-361. 
 132 
Pepper, C., T. T. Lin, et al. (2008). "Mcl-1 expression has in vitro and in vivo 
significance in chronic lymphocytic leukemia and is associated with other poor 
prognostic markers." Blood 112(9): 3807-3817. 
Perez-Galan, P., G. Roue, et al. (2007). "The BH3-mimetic GX15-070 synergizes with 
bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of 
Bak." Blood 109(10): 4441-4449. 
Petros, A. M., A. Medek, et al. (2001). "Solution structure of the antiapoptotic protein 
bcl-2." Proc Natl Acad Sci U S A 98(6): 3012-3017. 
Pleyer, L., A. Egle, et al. (2009). "Molecular and cellular mechanisms of CLL: novel 
therapeutic approaches." Nat Rev Clin Oncol 6(7): 405-418. 
Puthalakath, H., D. C. Huang, et al. (1999). "The proapoptotic activity of the Bcl-2 
family member Bim is regulated by interaction with the dynein motor complex." 
Mol Cell 3(3): 287-296. 
Raje, N., S. Kumar, et al. (2005). "Seliciclib (CYC202 or R-roscovitine), a small-
molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation 
of Mcl-1 in multiple myeloma." Blood 106(3): 1042-1047. 
Rampino, N., H. Yamamoto, et al. (1997). "Somatic frameshift mutations in the BAX 
gene in colon cancers of the microsatellite mutator phenotype." Science 
275(5302): 967-969. 
Rassenti, L. Z., L. Huynh, et al. (2004). "ZAP-70 compared with immunoglobulin heavy-
chain gene mutation status as a predictor of disease progression in chronic 
lymphocytic leukemia." N Engl J Med 351(9): 893-901. 
 133 
Rhodes, D. R., J. Yu, et al. (2004). "ONCOMINE: a cancer microarray database and 
integrated data-mining platform." Neoplasia 6(1): 1-6. 
Rinkenberger, J. L., S. Horning, et al. (2000). "Mcl-1 deficiency results in peri-
implantation embryonic lethality." Genes Dev 14(1): 23-27. 
Robak, T., A. Dmoszynska, et al. (2010). "Rituximab plus fludarabine and 
cyclophosphamide prolongs progression-free survival compared with fludarabine 
and cyclophosphamide alone in previously treated chronic lymphocytic 
leukemia." J Clin Oncol 28(10): 1756-1765. 
Roberts, A. W., J. F. Seymour, et al. (2012). "Substantial susceptibility of chronic 
lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax 
in patients with relapsed or refractory disease." J Clin Oncol 30(5): 488-496. 
Rubinstein, A. D., M. Eisenstein, et al. (2011). "The autophagy protein Atg12 associates 
with antiapoptotic Bcl-2 family members to promote mitochondrial apoptosis." 
Mol Cell 44(5): 698-709. 
Rust, R., G. Harms, et al. (2005). "High expression of Mcl-1 in ALK positive and 
negative anaplastic large cell lymphoma." J Clin Pathol 58(5): 520-524. 
Safa, A. R., C. J. Glover, et al. (1987). "Identification of the multidrug resistance-related 
membrane glycoprotein as an acceptor for calcium channel blockers." J Biol 
Chem 262(16): 7884-7888. 
Sattler, M., H. Liang, et al. (1997). "Structure of Bcl-xL-Bak peptide complex: 
recognition between regulators of apoptosis." Science 275(5302): 983-986. 
Schwickart, M., X. Huang, et al. (2010). "Deubiquitinase USP9X stabilizes MCL1 and 
promotes tumour cell survival." Nature 463(7277): 103-107. 
 134 
Seiler, T., H. Dohner, et al. (2006). "Risk stratification in chronic lymphocytic leukemia." 
Semin Oncol 33(2): 186-194. 
Shanafelt, T. D., J. C. Byrd, et al. (2006). "Narrative review: initial management of newly 
diagnosed, early-stage chronic lymphocytic leukemia." Ann Intern Med 145(6): 
435-447. 
Sheikholeslami, M. R., I. Jilani, et al. (2006). "Variations in the detection of ZAP-70 in 
chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis." 
Cytometry B Clin Cytom 70(4): 270-275. 
Shen, Y., J. Iqbal, et al. (2004). "BCL2 protein expression parallels its mRNA level in 
normal and malignant B cells." Blood 104(9): 2936-2939. 
Shi, J., Y. Zhou, et al. (2011). "Navitoclax (ABT-263) accelerates apoptosis during drug-
induced mitotic arrest by antagonizing Bcl-xL." Cancer Res 71(13): 4518-4526. 
Shimizu, S., T. Kanaseki, et al. (2004). "Role of Bcl-2 family proteins in a non-apoptotic 
programmed cell death dependent on autophagy genes." Nat Cell Biol 6(12): 
1221-1228. 
Stam, R. W., M. L. Den Boer, et al. (2010). "Association of high-level MCL-1 expression 
with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute 
lymphoblastic leukemia." Blood 115(5): 1018-1025. 
Stecca, B., C. Mas, et al. (2007). "Melanomas require HEDGEHOG-GLI signaling 
regulated by interactions between GLI1 and the RAS-MEK/AKT pathways." Proc 
Natl Acad Sci U S A 104(14): 5895-5900. 
Stewart, D. P., B. Koss, et al. (2010). "Ubiquitin-independent degradation of 
antiapoptotic MCL-1." Mol Cell Biol 30(12): 3099-3110. 
 135 
Suzuki, M., R. J. Youle, et al. (2000). "Structure of Bax: coregulation of dimer formation 
and intracellular localization." Cell 103(4): 645-654. 
Tagawa, H., S. Karnan, et al. (2005). "Genome-wide array-based CGH for mantle cell 
lymphoma: identification of homozygous deletions of the proapoptotic gene 
BIM." Oncogene 24(8): 1348-1358. 
Tait, S. W. and D. R. Green (2010). "Mitochondria and cell death: outer membrane 
permeabilization and beyond." Nat Rev Mol Cell Biol 11(9): 621-632. 
Thomas, A., C. Pepper, et al. (2000). "Bcl-2 and bax expression and chlorambucil-
induced apoptosis in the T-cells and leukaemic B-cells of untreated B-cell chronic 
lymphocytic leukaemia patients." Leuk Res 24(10): 813-821. 
Tse, C., A. R. Shoemaker, et al. (2008). "ABT-263: a potent and orally bioavailable Bcl-2 
family inhibitor." Cancer Res 68(9): 3421-3428. 
Tsujimoto, Y., J. Cossman, et al. (1985). "Involvement of the bcl-2 gene in human 
follicular lymphoma." Science 228(4706): 1440-1443. 
Tsujimoto, Y., L. R. Finger, et al. (1984). "Cloning of the chromosome breakpoint of 
neoplastic B cells with the t(14;18) chromosome translocation." Science 
226(4678): 1097-1099. 
Turkmen, S., M. Riehn, et al. (2011). "A BACH2-BCL2L1 fusion gene resulting from a 
t(6;20)(q15;q11.2) chromosomal translocation in the lymphoma cell line BLUE-
1." Genes Chromosomes Cancer 50(6): 389-396. 
Tzifi, F., C. Economopoulou, et al. (2012). "The Role of BCL2 Family of Apoptosis 
Regulator Proteins in Acute and Chronic Leukemias." Adv Hematol 2012: 
524308. 
 136 
Uren, R. T., G. Dewson, et al. (2007). "Mitochondrial permeabilization relies on BH3 
ligands engaging multiple prosurvival Bcl-2 relatives, not Bak." J Cell Biol 
177(2): 277-287. 
Van Bockstaele, F., B. Verhasselt, et al. (2009). "Prognostic markers in chronic 
lymphocytic leukemia: a comprehensive review." Blood Rev 23(1): 25-47. 
van Delft, M. F., A. H. Wei, et al. (2006). "The BH3 mimetic ABT-737 targets selective 
Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is 
neutralized." Cancer Cell 10(5): 389-399. 
Veis, D. J., C. M. Sorenson, et al. (1993). "Bcl-2-deficient mice demonstrate fulminant 
lymphoid apoptosis, polycystic kidneys, and hypopigmented hair." Cell 75(2): 
229-240. 
Ventura, A., A. G. Young, et al. (2008). "Targeted deletion reveals essential and 
overlapping functions of the miR-17 through 92 family of miRNA clusters." Cell 
132(5): 875-886. 
Veronese, L., O. Tournilhac, et al. (2008). "Low MCL-1 mRNA expression correlates 
with prolonged survival in B-cell chronic lymphocytic leukemia." Leukemia 
22(6): 1291-1293. 
Villunger, A., E. M. Michalak, et al. (2003). "p53- and drug-induced apoptotic responses 
mediated by BH3-only proteins puma and noxa." Science 302(5647): 1036-1038. 
Vogler, M., M. Butterworth, et al. (2009). "Concurrent up-regulation of BCL-XL and 
BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic 
lymphocytic leukemia." Blood 113(18): 4403-4413. 
 137 
Vogler, M., D. Dinsdale, et al. (2009). "Bcl-2 inhibitors: small molecules with a big 
impact on cancer therapy." Cell Death Differ 16(3): 360-367. 
Wei, G., A. A. Margolin, et al. (2012). "Chemical Genomics Identifies Small-Molecule 
MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency." Cancer 
Cell 21(4): 547-562. 
Wei, M. C., T. Lindsten, et al. (2000). "tBID, a membrane-targeted death ligand, 
oligomerizes BAK to release cytochrome c." Genes Dev 14(16): 2060-2071. 
Wei, M. C., W. X. Zong, et al. (2001). "Proapoptotic BAX and BAK: a requisite gateway 
to mitochondrial dysfunction and death." Science 292(5517): 727-730. 
Williamson, K. E., J. D. Kelly, et al. (1998). "Bcl-2/Bax ratios in chronic lymphocytic 
leukaemia and their correlation with in vitro apoptosis and clinical resistance." Br 
J Cancer 78(4): 553-554. 
Willis, S. N., L. Chen, et al. (2005). "Proapoptotic Bak is sequestered by Mcl-1 and Bcl-
xL, but not Bcl-2, until displaced by BH3-only proteins." Genes Dev 19(11): 
1294-1305. 
Wilson, W. H., O. A. O'Connor, et al. (2010). "Navitoclax, a targeted high-affinity 
inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of 
safety, pharmacokinetics, pharmacodynamics, and antitumour activity." Lancet 
Oncol 11(12): 1149-1159. 
Xiao, C., L. Srinivasan, et al. (2008). "Lymphoproliferative disease and autoimmunity in 
mice with increased miR-17-92 expression in lymphocytes." Nat Immunol 9(4): 
405-414. 
 138 
Yecies, D., N. E. Carlson, et al. (2010). "Acquired resistance to ABT-737 in lymphoma 
cells that up-regulate MCL-1 and BFL-1." Blood 115(16): 3304-3313. 
Yin, X. M., K. Wang, et al. (1999). "Bid-deficient mice are resistant to Fas-induced 
hepatocellular apoptosis." Nature 400(6747): 886-891. 
Youle, R. J. and A. Strasser (2008). "The BCL-2 protein family: opposing activities that 
mediate cell death." Nat Rev Mol Cell Biol 9(1): 47-59. 
Zenz, T., A. Krober, et al. (2008). "Monoallelic TP53 inactivation is associated with poor 
prognosis in chronic lymphocytic leukemia: results from a detailed genetic 
characterization with long-term follow-up." Blood 112(8): 3322-3329. 
Zha, H., C. Aime-Sempe, et al. (1996). "Proapoptotic protein Bax heterodimerizes with 
Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 
and BH2." J Biol Chem 271(13): 7440-7444. 
Zha, J., H. Harada, et al. (1996). "Serine phosphorylation of death agonist BAD in 
response to survival factor results in binding to 14-3-3 not BCL-X(L)." Cell 
87(4): 619-628. 
Zhong, Q., W. Gao, et al. (2005). "Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, 
catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis." Cell 121(7): 
1085-1095. 
Zong, W. X., L. C. Edelstein, et al. (1999). "The prosurvival Bcl-2 homolog Bfl-1/A1 is a 
direct transcriptional target of NF-kappaB that blocks TNFalpha-induced 
apoptosis." Genes Dev 13(4): 382-387. 
 139 
Zong, W. X., T. Lindsten, et al. (2001). "BH3-only proteins that bind pro-survival Bcl-2 
family members fail to induce apoptosis in the absence of Bax and Bak." Genes 
Dev 15(12): 1481-1486. 
Zwiebel, J. A. and B. D. Cheson (1998). "Chronic lymphocytic leukemia: staging and 
prognostic factors." Semin Oncol 25(1): 42-59. 
 
 
